Tumor vaccine and application thereof
By designing a polypeptide vaccine, multi-antigen tandem containing multiple targeted antigen fragments, the problems of insufficient antigen and immune escape of existing tumor vaccines have been solved, achieving a wider T-cell response and stronger anti-tumor effect.
Patent Information
- Application Number
- CN202410990683.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-04-29
- Filing Date
- 2024-07-22
- Publication Date
- 2024-11-08
AI Technical Summary
Existing tumor vaccines face immune escape problems caused by insufficient or loss of antigens when treating tumors, making it difficult to stimulate a wide range of specific T-cell responses, and there are challenges in tumor antigen screening and design.
A polypeptide vaccine is designed, which contains multiple targeted antigen fragments, and is linked by a peptide linking, selected from antigen epitopes such as ACTL8, BRDT, FOXI3, GNGT1, SMC1B, PLAC1, MAGEA1, MAGEA3, MAGEA4, MAGEA6, MAGEA10 and MAGEA11, Multi-antigen tandem and new functional elements are added to promote multi-antigen presentation and T-cell response.
Through multi-antigen tandem and the addition of new functional elements, immune escape caused by insufficient monoantigen is overcome, the widespreadness of T-cell response and anti-tumor effect are improved, and the immunogenicity and therapeutic potential of the vaccine are enhanced.
Smart Images

Figure SMS_2 
Figure SMS_3 
Figure SMS_4
Abstract
Description
[0001] priority
[0002] This application claims the benefit and priority of PCT international application No. PCT / CN2024 / 090619, filed on April 29, 2024, the entire contents of which are incorporated herein by reference in their entirety. Technical Field
[0003] The present disclosure belongs to the field of biotechnology, and in particular, relates to tumor vaccines and applications thereof. Background Art
[0004] Tumors are important diseases that affect human health and have become the second leading cause of death worldwide. Tumor treatment mainly includes traditional surgical treatment, radiotherapy, chemotherapy, and new treatment methods such as targeted therapy and immunotherapy that have developed rapidly in recent years. Although existing immunotherapy has achieved remarkable results in the field of tumor treatment, tumor vaccines have their unique advantages. For example, tumor vaccines can target intracellular antigens other than tumor-specific surface antigens and may even trigger new tumor-specific T cell responses. However, the number of clinical trials of cancer vaccines that have been carried out is limited, and its therapeutic effect and detailed and clear principles require further exploration and confirmation by researchers.
[0005] Due to the heterogeneity of tumors, how to screen for broad-spectrum universal antigens is a major scientific and technological issue faced in the design of mRNA vaccines. The key to tumor vaccine design is to select appropriate tumor antigens and epitopes, improve the safety and immunogenicity of the vaccine, and effectively stimulate the body's immune response and produce anti-tumor effects. Solid tumors are highly heterogeneous. In theory, tumor vaccines designed based on a multi-antigen target strategy can induce a wider range of specific T cell responses and overcome immune escape caused by insufficient or lost antigens. Their clinical efficacy potential is better than that of single-target vaccines. mRNA vaccines can encode multiple antigens and more fully demonstrate their technical advantages when multiple epitopes are connected in series. Summary of the invention
[0006] The present disclosure provides a polypeptide comprising one or more targeting antigen fragments, wherein the antigen fragments comprise one or more antigen epitope peptides, and the one or more antigen fragments are connected by a connecting peptide, wherein the antigen is selected from one or more of ACTL8, BRDT, FOXI3, GNGT1, SMC1B, PLAC1, MAGEA1, MAGEA3, MAGEA4, MAGEA6, MAGEA10 and MAGEA11.
[0007] In some embodiments, the antigens further comprise one or more of TP53.175R / H, TP53.220Y / C, PIK3CA.545E / K, and KRAS.12G / D.
[0008] In some embodiments, the antigenic fragment comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 108-162.
[0009] In some embodiments, the polypeptide comprises 20 antigenic fragments, each of which is an amino acid sequence selected from SEQ ID NOs: 108-127.
[0010] In some embodiments, the polypeptide comprises 20 antigenic fragments, each of which is an amino acid sequence selected from SEQ ID NOs: 128-147.
[0011] In some embodiments, the polypeptide comprises 15 antigenic fragments, each of which is an amino acid sequence selected from SEQ ID NOs: 148-162.
[0012] In some embodiments, the antigenic epitope peptide comprises an amino acid sequence selected from SEQ ID NOs: 1-107 or SEQ ID NOs: 163-225.
[0013] In some embodiments, the polypeptide comprises:
[0014] (1) an antigenic epitope peptide targeting ACTL8, wherein the antigenic epitope peptide comprises an amino acid sequence shown in SEQ ID NOs: 3 or 7;
[0015] (2) an antigenic epitope peptide targeting SMC1B, wherein the antigenic epitope peptide comprises an amino acid sequence shown in SEQ ID NO: 28;
[0016] (3) an antigenic epitope peptide targeting FOXI3, wherein the antigenic epitope peptide comprises an amino acid sequence shown in SEQ ID NO: 12;
[0017] (4) an antigenic epitope peptide targeting GNGT1, wherein the antigenic epitope peptide comprises an amino acid sequence shown in SEQ ID NO: 13;
[0018] (5) An antigenic epitope peptide targeting PLAC1, wherein the antigenic epitope peptide comprises:
[0019] (i) the amino acid sequence shown in SEQ ID NO: 23 or SEQ ID NO: 163;
[0020] (ii) the amino acid sequence shown in SEQ ID NO: 164; and
[0021] (iii) the amino acid sequence shown in SEQ ID NO: 165;
[0022] (6) an antigenic epitope peptide targeting BRDT, wherein the antigenic epitope peptide comprises an amino acid sequence shown in SEQ ID NO: 9;
[0023] (7) an antigenic epitope peptide targeting MAGEA1, wherein the antigenic epitope peptide comprises an amino acid sequence shown in SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 63, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168 or SEQ ID NO: 169;
[0024] (8) An antigenic epitope peptide targeting MAGEA4, the antigenic epitope peptide comprising:
[0025] (i) the amino acid sequence shown in SEQ ID NO: 19, SEQ ID NO: 70, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172 or SEQ ID NO: 173; and
[0026] (ii) the amino acid sequence shown in SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:174, SEQ ID NO:175 or SEQ ID NO:176;
[0027] (9) An antigenic epitope peptide targeting MAGEA6, the antigenic epitope peptide comprising:
[0028] (i) the amino acid sequence shown in SEQ ID NO: 177, SEQ ID NO: 178 or SEQ ID NO: 179; and
[0029] (ii) the amino acid sequence shown in SEQ ID NO: 180;
[0030] (10) An antigenic epitope peptide targeting MAGEA3, the antigenic epitope peptide comprising:
[0031] (i) the amino acid sequence shown in SEQ ID NO: 181, SEQ ID NO: 182 or SEQ ID NO: 183; and
[0032] (ii) the amino acid sequence shown in SEQ ID NO: 184;
[0033] (11) An antigenic epitope peptide targeting MAGEA11, the antigenic epitope peptide comprising:
[0034] (i) the amino acid sequence shown in SEQ ID NO: 185, SEQ ID NO: 186 or SEQ ID NO: 187; and
[0035] (ii) the amino acid sequence shown in SEQ ID NO: 15, SEQ ID NO: 188 or SEQ ID NO: 189;
[0036] (12) An antigenic epitope peptide targeting MAGEA10, the antigenic epitope peptide comprising:
[0037] (i) the amino acid sequence shown in SEQ ID NO: 14, SEQ ID NO: 190, SEQ ID NO: 191 or SEQ ID NO: 192; and
[0038] (ii) the amino acid sequence shown in SEQ ID NO: 193 or SEQ ID NO: 194;
[0039] (13) an antigenic epitope peptide targeting TP53.175R / H, wherein the antigenic epitope peptide comprises the amino acid sequence shown in SEQ ID NO: 195; and
[0040] (14) An antigenic epitope peptide targeting TP53.220Y / C, wherein the antigenic epitope peptide comprises the amino acid sequence shown in SEQ ID NO: 196.
[0041] In some embodiments, the polypeptide comprises:
[0042] (1) An antigenic epitope peptide targeting SMC1B, the antigenic epitope peptide comprising:
[0043] (i) the amino acid sequence shown in SEQ ID NOs:93, SEQ ID NOs:101 or SEQ ID NOs:106; and
[0044] (ii) the amino acid sequence shown in SEQ ID NOs: 104;
[0045] (2) An antigenic epitope peptide targeting BRDT, the antigenic epitope peptide comprising:
[0046] (i) the amino acid sequence shown in SEQ ID NO: 42 or SEQ ID NO: 46; and
[0047] (ii) the amino acid sequence shown in SEQ ID NO: 50;
[0048] (3) an antigenic epitope peptide targeting GNGT1, wherein the antigenic epitope peptide comprises the amino acid sequences shown in SEQ ID NO: 54 and SEQ ID NO: 55;
[0049] (4) an antigenic epitope peptide targeting FOXI3, wherein the antigenic epitope peptide comprises the amino acid sequence shown in SEQ ID NO: 53;
[0050] (5) an antigenic epitope peptide targeting ACTL8, wherein the antigenic epitope peptide comprises the amino acid sequences shown in SEQ ID NO: 40 and SEQ ID NO: 31;
[0051] (6) An antigenic epitope peptide targeting MAGEA6, the antigenic epitope peptide comprising:
[0052] (i) the amino acid sequence shown in SEQ ID NO: 73 or SEQ ID NO: 78; and
[0053] (ii) the amino acid sequence shown in SEQ ID NO: 74;
[0054] (7) an antigenic epitope peptide targeting MAGEA11, wherein the antigenic epitope peptide comprises the amino acid sequences shown in SEQ ID NO: 59 and SEQ ID NO: 60;
[0055] (8) an antigenic epitope peptide targeting MAGEA3, wherein the antigenic epitope peptide comprises the amino acid sequences shown in SEQ ID NO: 197 and SEQ ID NO: 65;
[0056] (9) an antigenic epitope peptide targeting MAGEA4, wherein the antigenic epitope peptide comprises the amino acid sequences shown in SEQ ID NO: 71 and SEQ ID NO: 72;
[0057] (10) an antigenic epitope peptide targeting MAGEA10, wherein the antigenic epitope peptide comprises the amino acid sequence shown in SEQ ID NO: 57;
[0058] (11) An antigenic epitope peptide targeting MAGEA1, the antigenic epitope peptide comprising:
[0059] (i) the amino acid sequence shown in SEQ ID NO:61, SEQ ID NO:62 or SEQ ID NO:198; and
[0060] (ii) the amino acid sequence shown in SEQ ID NO: 199, SEQ ID NO: 200 or SEQ ID NO: 201;
[0061] (12) an antigenic epitope peptide targeting PIK3CA.545E / K, wherein the antigenic epitope peptide comprises the amino acid sequence shown in SEQ ID NO: 202; and
[0062] (13) An antigenic epitope peptide targeting KRAS.12G / D, wherein the antigenic epitope peptide comprises the amino acid sequence shown in SEQ ID NO: 203.
[0063] In some embodiments, the polypeptide comprises:
[0064] (1) An antigenic epitope peptide targeting ACTL8, the antigenic epitope peptide comprising:
[0065] (i) the amino acid sequence shown in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:36 or SEQ ID NO:38; and
[0066] (ii) the amino acid sequence shown in SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 34 or SEQ ID NO: 40;
[0067] (2) An antigenic epitope peptide targeting GNGT1, wherein the antigenic epitope peptide comprises:
[0068] (i) the amino acid sequence shown in SEQ ID NO: 13 or SEQ ID NO: 54; and
[0069] (ii) the amino acid sequence shown in SEQ ID NO: 55;
[0070] (3) An antigenic epitope peptide targeting MAGEA1, wherein the antigenic epitope peptide comprises:
[0071] (i) the amino acid sequence set forth in SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218 or SEQ ID NO:219; and
[0072] (ii) the amino acid sequence set forth in SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 63, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 220, SEQ ID NO: 221 or SEQ ID NO: 222;
[0073] (4) An antigenic epitope peptide targeting MAGEA6, wherein the antigenic epitope peptide comprises:
[0074] (i) the amino acid sequence shown in SEQ ID NO: 208 or SEQ ID NO: 77;
[0075] (ii) the amino acid sequence shown in SEQ ID NO: 180 or SEQ ID NO: 223; and
[0076] (iii) the amino acid sequence shown in SEQ ID NO: 209;
[0077] (5) An antigenic epitope peptide targeting MAGEA3, wherein the antigenic epitope peptide comprises:
[0078] (i) the amino acid sequence shown in SEQ ID NO: 67;
[0079] (ii) the amino acid sequence shown in SEQ ID NO: 210, SEQ ID NO: 211 or SEQ ID NO: 212;
[0080] (iii) the amino acid sequence shown in SEQ ID NO: 213; and
[0081] (iv) the amino acid sequence shown in SEQ ID NO: 184 or SEQ ID NO: 65;
[0082] (6) An antigenic epitope peptide targeting SMC1B, the antigenic epitope peptide comprising:
[0083] (i) the amino acid sequence shown in SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:185, SEQ ID NO:94, SEQ ID NO:105, SEQ ID NO:95 or SEQ ID NO:89;
[0084] (ii) the amino acid sequence shown in SEQ ID NO: 81 or SEQ ID NO: 99; and
[0085] (iii) the amino acid sequence shown in SEQ ID NO: 27 or SEQ ID NO: 80;
[0086] (7) An antigenic epitope peptide targeting MAGEA4, the antigenic epitope peptide comprising:
[0087] (i) the amino acid sequence shown in SEQ ID NO:70, SEQ ID NO:19, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172 or SEQ ID NO:173; and
[0088] (ii) the amino acid sequence set forth in SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176 or SEQ ID NO:214;
[0089] (8) an antigenic epitope peptide targeting MAGEA11, wherein the antigenic epitope peptide comprises an amino acid sequence shown in SEQ ID NO: 15, SEQ ID NO: 188, SEQ ID NO: 189, SEQ ID NO: 58 or SEQ ID NO: 60;
[0090] (9) An antigenic epitope peptide targeting BRDT, wherein the antigenic epitope peptide comprises the amino acid sequence shown in SEQ ID NO: 11, SEQ ID NO: 43 or SEQ ID NO: 45.
[0091] In some embodiments, the polypeptide comprises the amino acid sequence shown in SEQ ID NO:226, SEQ ID NO:227 or SEQ ID NO:228.
[0092] In a specific embodiment, the polypeptide disclosed herein comprises 20 antigen fragments, wherein the one or more antigen fragments are connected by connecting peptides, wherein the antigen fragments are selected from ACTL8, SMC1B, FOXI3, GNGT1, PLAC1, BRDT, MAGEA1, MAGEA4, MAGEA6, MAGEA3, MAGEA11, MAGEA10, TP53.175R / H and TP53.220Y / C shown in SEQ ID NOs: 108-127, and the antigen fragments comprise one or more antigen epitope peptides, wherein the antigen epitope peptides are:
[0093] (1) an antigenic epitope peptide targeting ACTL8, wherein the antigenic epitope peptide comprises an amino acid sequence shown in SEQ ID NOs: 3 or 7;
[0094] (2) an antigenic epitope peptide targeting SMC1B, wherein the antigenic epitope peptide comprises an amino acid sequence shown in SEQ ID NO: 28;
[0095] (3) an antigenic epitope peptide targeting FOXI3, wherein the antigenic epitope peptide comprises an amino acid sequence shown in SEQ ID NO: 12;
[0096] (4) an antigenic epitope peptide targeting GNGT1, wherein the antigenic epitope peptide comprises an amino acid sequence shown in SEQ ID NO: 13;
[0097] (5) An antigenic epitope peptide targeting PLAC1, wherein the antigenic epitope peptide comprises:
[0098] (i) the amino acid sequence shown in SEQ ID NO: 23 or SEQ ID NO: 163;
[0099] (ii) the amino acid sequence shown in SEQ ID NO: 164; and
[0100] (iii) the amino acid sequence shown in SEQ ID NO: 165;
[0101] (6) an antigenic epitope peptide targeting BRDT, wherein the antigenic epitope peptide comprises an amino acid sequence shown in SEQ ID NO: 9;
[0102] (7) an antigenic epitope peptide targeting MAGEA1, wherein the antigenic epitope peptide comprises an amino acid sequence shown in SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 63, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168 or SEQ ID NO: 169;
[0103] (8) An antigenic epitope peptide targeting MAGEA4, the antigenic epitope peptide comprising:
[0104] (i) the amino acid sequence shown in SEQ ID NO: 19, SEQ ID NO: 70, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172 or SEQ ID NO: 173; and
[0105] (ii) the amino acid sequence shown in SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:174, SEQ ID NO:175 or SEQ ID NO:176;
[0106] (9) An antigenic epitope peptide targeting MAGEA6, the antigenic epitope peptide comprising:
[0107] (i) the amino acid sequence shown in SEQ ID NO: 177, SEQ ID NO: 178 or SEQ ID NO: 179; and
[0108] (ii) the amino acid sequence shown in SEQ ID NO: 180;
[0109] (10) An antigenic epitope peptide targeting MAGEA3, the antigenic epitope peptide comprising:
[0110] (i) the amino acid sequence shown in SEQ ID NO: 181, SEQ ID NO: 182 or SEQ ID NO: 183; and
[0111] (ii) the amino acid sequence shown in SEQ ID NO: 184;
[0112] (11) An antigenic epitope peptide targeting MAGEA11, the antigenic epitope peptide comprising:
[0113] (i) the amino acid sequence shown in SEQ ID NO: 185, SEQ ID NO: 186 or SEQ ID NO: 187; and
[0114] (ii) the amino acid sequence shown in SEQ ID NO: 15, SEQ ID NO: 188 or SEQ ID NO: 189;
[0115] (12) An antigenic epitope peptide targeting MAGEA10, the antigenic epitope peptide comprising:
[0116] (i) the amino acid sequence shown in SEQ ID NO: 14, SEQ ID NO: 190, SEQ ID NO: 191 or SEQ ID NO: 192; and
[0117] (ii) the amino acid sequence shown in SEQ ID NO: 193 or SEQ ID NO: 194;
[0118] (13) an antigenic epitope peptide targeting TP53.175R / H, wherein the antigenic epitope peptide comprises the amino acid sequence shown in SEQ ID NO: 195; and
[0119] (14) An antigenic epitope peptide targeting TP53.220Y / C, wherein the antigenic epitope peptide comprises the amino acid sequence shown in SEQ ID NO: 196.
[0120] In a specific embodiment, the antigen comprises the amino acid sequence shown in SEQ ID NO:226.
[0121] In a specific embodiment, the polypeptide disclosed herein comprises 20 antigen fragments, wherein the one or more antigen fragments are connected by connecting peptides, wherein the antigen fragments are selected from SMC1B, BRDT, GNGT1, FOXI3, ACTL8, MAGEA6, MAGEA11, MAGEA3, MAGEA4, MAGEA10, MAGEA1, PIK3CA.545E / K and KRAS.12G / D shown in SEQ ID NOs: 128-147, and the antigen fragments comprise one or more antigen epitope peptides, wherein the antigen epitope peptides are:
[0122] (1) An antigenic epitope peptide targeting SMC1B, the antigenic epitope peptide comprising:
[0123] (i) the amino acid sequence shown in SEQ ID NOs:93, SEQ ID NOs:101 or SEQ ID NOs:106; and
[0124] (ii) the amino acid sequence shown in SEQ ID NOs: 104;
[0125] (2) An antigenic epitope peptide targeting BRDT, the antigenic epitope peptide comprising:
[0126] (i) the amino acid sequence shown in SEQ ID NO: 42 or SEQ ID NO: 46; and
[0127] (ii) the amino acid sequence shown in SEQ ID NO: 50;
[0128] (3) an antigenic epitope peptide targeting GNGT1, wherein the antigenic epitope peptide comprises the amino acid sequences shown in SEQ ID NO: 54 and SEQ ID NO: 55;
[0129] (4) an antigenic epitope peptide targeting FOXI3, wherein the antigenic epitope peptide comprises the amino acid sequence shown in SEQ ID NO: 53;
[0130] (5) an antigenic epitope peptide targeting ACTL8, wherein the antigenic epitope peptide comprises the amino acid sequences shown in SEQ ID NO: 40 and SEQ ID NO: 31;
[0131] (6) An antigenic epitope peptide targeting MAGEA6, the antigenic epitope peptide comprising:
[0132] (i) the amino acid sequence shown in SEQ ID NO: 73 or SEQ ID NO: 78; and
[0133] (ii) the amino acid sequence shown in SEQ ID NO: 74;
[0134] (7) an antigenic epitope peptide targeting MAGEA11, wherein the antigenic epitope peptide comprises the amino acid sequences shown in SEQ ID NO: 59 and SEQ ID NO: 60;
[0135] (8) an antigenic epitope peptide targeting MAGEA3, wherein the antigenic epitope peptide comprises the amino acid sequences shown in SEQ ID NO: 197 and SEQ ID NO: 65;
[0136] (9) an antigenic epitope peptide targeting MAGEA4, wherein the antigenic epitope peptide comprises the amino acid sequences shown in SEQ ID NO: 71 and SEQ ID NO: 72;
[0137] (10) an antigenic epitope peptide targeting MAGEA10, wherein the antigenic epitope peptide comprises the amino acid sequence shown in SEQ ID NO: 57;
[0138] (11) An antigenic epitope peptide targeting MAGEA1, the antigenic epitope peptide comprising:
[0139] (i) the amino acid sequence shown in SEQ ID NO:61, SEQ ID NO:62 or SEQ ID NO:198; and
[0140] (ii) the amino acid sequence shown in SEQ ID NO: 199, SEQ ID NO: 200 or SEQ ID NO: 201;
[0141] (12) an antigenic epitope peptide targeting PIK3CA.545E / K, wherein the antigenic epitope peptide comprises the amino acid sequence shown in SEQ ID NO: 202; and
[0142] (13) An antigenic epitope peptide targeting KRAS.12G / D, wherein the antigenic epitope peptide comprises the amino acid sequence shown in SEQ ID NO: 203.
[0143] In a specific embodiment, the polypeptide comprises the amino acid sequence shown in SEQ ID NO:227.
[0144] In a specific embodiment, the polypeptide disclosed herein comprises 15 antigen fragments, wherein the one or more antigen fragments are connected by connecting peptides, wherein the antigen fragments are selected from ACTL8, GNGT1, MAGEA1, MAGEA6, MAGEA3, SMC1B, MAGEA4, MAGEA11 and BRDT shown in SEQ ID NOs: 148-162, and the antigen fragments comprise one or more antigen epitope peptides, wherein the antigen epitope peptides are:
[0145] (1) An antigenic epitope peptide targeting ACTL8, the antigenic epitope peptide comprising:
[0146] (i) the amino acid sequence shown in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:36 or SEQ ID NO:38; and
[0147] (ii) the amino acid sequence shown in SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 34 or SEQ ID NO: 40;
[0148] (2) An antigenic epitope peptide targeting GNGT1, wherein the antigenic epitope peptide comprises:
[0149] (i) the amino acid sequence shown in SEQ ID NO: 13 or SEQ ID NO: 54; and
[0150] (ii) the amino acid sequence shown in SEQ ID NO: 55;
[0151] (3) An antigenic epitope peptide targeting MAGEA1, wherein the antigenic epitope peptide comprises:
[0152] (i) the amino acid sequence set forth in SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218 or SEQ ID NO:219; and
[0153] (ii) the amino acid sequence set forth in SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 63, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 220, SEQ ID NO: 221 or SEQ ID NO: 222;
[0154] (4) An antigenic epitope peptide targeting MAGEA6, wherein the antigenic epitope peptide comprises:
[0155] (i) the amino acid sequence shown in SEQ ID NO: 208 or SEQ ID NO: 77;
[0156] (ii) the amino acid sequence shown in SEQ ID NO: 180 or SEQ ID NO: 223; and
[0157] (iii) the amino acid sequence shown in SEQ ID NO: 209;
[0158] (5) An antigenic epitope peptide targeting MAGEA3, wherein the antigenic epitope peptide comprises:
[0159] (i) the amino acid sequence shown in SEQ ID NO: 67;
[0160] (ii) the amino acid sequence shown in SEQ ID NO: 210, SEQ ID NO: 211 or SEQ ID NO: 212;
[0161] (iii) the amino acid sequence shown in SEQ ID NO: 213; and
[0162] (iv) the amino acid sequence shown in SEQ ID NO: 184 or SEQ ID NO: 65;
[0163] (6) An antigenic epitope peptide targeting SMC1B, the antigenic epitope peptide comprising:
[0164] (i) the amino acid sequence shown in SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:185, SEQ ID NO:94, SEQ ID NO:105, SEQ ID NO:95 or SEQ ID NO:89;
[0165] (ii) the amino acid sequence shown in SEQ ID NO: 81 or SEQ ID NO: 99; and
[0166] (iii) the amino acid sequence shown in SEQ ID NO: 27 or SEQ ID NO: 80;
[0167] (7) An antigenic epitope peptide targeting MAGEA4, the antigenic epitope peptide comprising:
[0168] (i) the amino acid sequence shown in SEQ ID NO:70, SEQ ID NO:19, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172 or SEQ ID NO:173; and
[0169] (ii) the amino acid sequence set forth in SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176 or SEQ ID NO:214;
[0170] (8) an antigenic epitope peptide targeting MAGEA11, wherein the antigenic epitope peptide comprises an amino acid sequence shown in SEQ ID NO: 15, SEQ ID NO: 188, SEQ ID NO: 189, SEQ ID NO: 58 or SEQ ID NO: 60;
[0171] (9) An antigenic epitope peptide targeting BRDT, wherein the antigenic epitope peptide comprises the amino acid sequence shown in SEQ ID NO: 11, SEQ ID NO: 43 or SEQ ID NO: 45.
[0172] In a specific embodiment, the polypeptide comprises the amino acid sequence shown in SEQ ID NO:228.
[0173] In some embodiments, the polypeptide C-terminus further comprises a Th cell epitope PADRE and a major histocompatibility complex (MHC) class I transmembrane and trafficking domain (MITD).
[0174] In some embodiments, the N-terminus of the polypeptide comprises a signal peptide.
[0175] In some embodiments, the connecting peptide is a sequence as shown in SEQ ID NO: 235-236.
[0176] In some embodiments, the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 229-231.
[0177] In some specific embodiments, the polypeptide is selected from the amino acid sequence shown in SEQ ID NO: 229-231.
[0178] In another aspect, the present disclosure provides a linear epitope peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-107 and SEQ ID NOs: 163-225.
[0179] In some embodiments, the epitope peptide targets one or more antigens selected from the group consisting of ACTL8, BRDT, FOXI3, GNGT1, SMC1B, PLAC1, MAGEA1, MAGEA3, MAGEA4, MAGEA6, MAGEA10 and / or MAGEA11.
[0180] In some embodiments, the linear epitope peptide is selected from one or more of the following:
[0181] (1) a linear epitope peptide targeting ACTL8, comprising an amino acid sequence selected from SEQ ID NOs: 1-7 and SEQ ID NOs: 29-41;
[0182] (2) a linear epitope peptide targeting BRDT, comprising an amino acid sequence selected from SEQ ID NOs: 8-11 and SEQ ID NOs: 42-52;
[0183] (3) a linear epitope peptide targeting FOXI3, comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 12 and SEQ ID NO: 53;
[0184] (4) a linear epitope peptide targeting GNGT1, comprising an amino acid sequence selected from SEQ ID NOs: 13 and SEQ ID NOs: 54-56;
[0185] (5) a linear epitope peptide targeting SMC1B, comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 24-28, SEQ ID NOs: 79-107, and SEQ ID NO: 185;
[0186] (6) a linear epitope peptide targeting PLAC1, comprising an amino acid sequence selected from SEQ ID NO: 23 and SEQ ID NOs: 163-165;
[0187] (7) a linear epitope peptide targeting MAGEA1, comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 16-17, SEQ ID NOs: 61-63, SEQ ID NOs: 166-169, SEQ ID NOs: 198-201, and SEQ ID NOs: 204-207;
[0188] (8) a linear epitope peptide targeting MAGEA3, comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NOs: 64-68, SEQ ID NOs: 181-184, SEQ ID NO: 197, and SEQ ID NOs: 210-213;
[0189] (9) a linear epitope peptide targeting MAGEA4, comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 19-21, SEQ ID NOs: 69-72, SEQ ID NOs: 170-176, SEQ ID NO: 214, and SEQ ID NOs: 224-225;
[0190] (10) a linear epitope peptide targeting MAGEA6, comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 22, SEQ ID NOs: 73-78, SEQ ID NOs: 177-180, SEQ ID NOs: 208-209 and SEQ ID NO: 223;
[0191] (11) a linear epitope peptide targeting MAGEA10, comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 57, and SEQ ID NOs: 190-194; and
[0192] (12) A linear epitope peptide targeting MAGEA11, comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NOs: 58-60, and SEQ ID NOs: 185-189.
[0193] In yet another aspect, the present disclosure provides a nucleic acid comprising a nucleotide sequence encoding the polypeptide as described above or the linear epitope peptide as described above.
[0194] In yet another aspect, the present disclosure provides an RNA nucleic acid molecule comprising an open reading frame encoding the polypeptide as described above or a nucleic acid sequence thereof.
[0195] In yet another aspect, the present disclosure provides a tumor-associated antigen vaccine comprising the RNA nucleic acid molecule as described above.
[0196] In some embodiments, the RNA nucleic acid molecule is mRNA.
[0197] In yet another aspect, the present disclosure provides a pharmaceutical composition comprising the polypeptide as described above, the linear epitope peptide as described above, the nucleic acid as described above, the RNA nucleic acid molecule as described above, or the tumor-associated antigen vaccine as described above.
[0198] Use of the aforementioned polypeptide, the aforementioned linear epitope peptide, the aforementioned nucleic acid, the aforementioned RNA nucleic acid molecule, the aforementioned tumor-associated antigen vaccine or the aforementioned pharmaceutical composition in the preparation of a drug for treating and preventing a disease.
[0199] In some embodiments, the disease is selected from esophageal squamous cell carcinoma, lung squamous cell carcinoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, gastric cancer, lung adenocarcinoma, colon cancer, and rectal cancer.
[0200] Beneficial Effects
[0201] The present invention discloses de novo discovery and screening of tumor antigens based on a database, and combines immune mass spectrometry and AI algorithms to screen high-frequency HLA-I antigen sequences. By connecting multiple antigens in series and adding new functional elements, it can promote multi-antigen presentation and T cell response, and overcome immune escape caused by insufficient or lost single antigens. BRIEF DESCRIPTION OF THE DRAWINGS
[0202] The present disclosure can be more fully understood with reference to the following drawings.
[0203] Figure 1 The screening process of esophageal squamous cell carcinoma antigen targets and epitopes is shown.
[0204] Figure 2 shows the results of bioinformatics analysis of esophageal squamous cell carcinoma targets, A shows the gene expression difference analysis; B shows the screening gene heat map; C shows the TPM expression level of the screening gene.
[0205] Figure 3 Analysis of antigen expression ratios in various tumors is shown.
[0206] Figure 4 The statistical graph of high expression ratio of ECVAC target RNA in tumor tissues of esophageal cancer patients is shown, N=132.
[0207] Figure 5 HLA-A*02:01 antigen peptide affinity test results (cElisa) are shown.
[0208] Figure 6 The results of affinity testing of HLA-A*02:01 antigen peptide (cell-loaded peptide) are shown.
[0209] Figure 7 The results of HLA-A*11:01 antigen peptide affinity testing (cElisa) are shown.
[0210] Figure 8 The results of affinity testing of HLA-A*11:01 antigen peptide (cell-loaded peptide) are shown.
[0211] Fig. 9 A schematic diagram of the ECVAC-A2 / 11 mRNA design is shown.
[0212] Fig.10The results of non-denaturing gel electrophoresis for detecting mRNA mobility are shown, wherein M1: marker, Lane 1-7: ECVAC-A2 / 11-V1.0, ECVAC-A2 / 11-V1.1, ECVAC-A2 / 11-V1.2, ECVAC-A2 / 11-V1.3, ECVAC-A2 / 11-V1.4, ECVAC-A2 / 11-V1.5, ECVAC-A2 / 11-V1.6, Lane 8-14: ECVAC-A2-V1.0, ECVAC -A2-V1.1, ECVAC-A2-V1.2, ECVAC-A2-V1.3, ECVAC-A2-V1.4, ECVAC-A2-V1.5, ECVAC-A2-V1.6, Lane15~20: ECVAC -A11-V1.0, ECVAC-A11-V1.1, ECVAC-A11-V1.2, ECVAC-A11-V1.3, ECVAC-A11-V1.4, ECVAC-A11-V1.5; M2: marker.
[0213] Fig.11 The qPCR detection of mRNA intracellular expression level is shown, wherein (A) is the qPCR detection of mRNA intracellular expression level by ECVAC-A2 transfection; (B) is the qPCR detection of mRNA intracellular expression level by ECVAC-A11 transfection; (C) is the qPCR detection of mRNA intracellular expression level by ECVAC-A2 / 11 transfection.
[0214] Fig.12 The Cell free system is used to detect the in vitro translation level of mRNA, wherein (A) is the in vitro translation level of ECVAC-A2; (B) is the in vitro translation level of ECVAC-A11; and (C) is the in vitro translation level of ECVAC-A2 / 11.
[0215] Fig.13 Shown are the frequencies of single HLA epitope vaccine antigen-specific T cells in HLA-A2.1 transgenic mice.
[0216] Fig.14 Shown are the frequencies of single HLA epitope vaccine antigen-specific T cells in HLA-A11.1 transgenic mice.
[0217] Fig.15 The frequencies of vaccine antigen-specific T cells in HLA-A2.1 transgenic mice are shown, where A. is the comparison result between each peptide library group; B. is the overall comparison result between groups.
[0218] Fig.16The frequencies of vaccine antigen-specific T cells in HLA-A11.1 transgenic mice are shown, where A. is the comparison result between peptide library groups with different optimized sequences; B. is the comparison result between groups with different optimized sequences.
[0219] Fig.17 Figure 1 shows the biological activity detection of human PBMC after ECVAC in vitro expansion. Figure A shows the results of intracellular cytokine flow cytometry detection. Appropriate amounts of scanning peptide library and brefeldin A were added to the expanded T cells in the control group and the experimental group, and flow cytometry was performed after culturing at 37°C for about 16 hours. Figures B and C show that luciferase-based CTL cytotoxicity assays were performed using KYSE-410 (B) or KYSE-410-A2.1 (C) transfected with luciferase mRNA as target cells and the two groups of expanded T cells as effector cells.
[0220] Fig.18 Figures A and B show the killing results of tumor target cells by mouse spleen T cells after immunization with ECVAC. Figures A and B show the killing results of T cells isolated from spleen of HLA-A2.1 mice immunized with PBS or ECVAC (labeled Vaccine in the figure) and co-incubated with (A) MC38-A2.1-HHD or (B) MC38-A2.1-HHD-EC at an effector-target ratio of 5:1 and 40:1 for 24 hours; Figures C and D show the killing results of T cells isolated from spleen of HLA-A11.1 mice immunized with PBS or ECVAC (labeled Vaccine in the figure) and co-incubated with (C) MC38-A11.1-HHD or (D) MC38-A11.1-HHD-EC at an effector-target ratio of 10:1 and 40:1 for 24 hours.
[0221] Fig.19 The therapeutic effects of ECVAC in two transgenic mouse tumor models are shown. Figure A shows the schematic diagram of the experimental design; Figure B shows the results of the HLA-A2.1 transgenic mouse tumor model; Figure C shows the results of the HLA-A11.1 transgenic mouse tumor model.
[0222] Fig. 20 The tumor growth curve of the experimental animals after the start of treatment is shown, *P<0.05, **P<0.01. DETAILED DESCRIPTION
[0223] The following description of the present disclosure is intended only to illustrate various different embodiments of the present disclosure. Therefore, the specific modifications discussed should not be interpreted as limiting the scope of the present disclosure. It is obvious to those skilled in the art that various different equivalents, changes and modifications can be made without departing from the scope of the present disclosure, and it should be understood that these equivalent embodiments will be included herein. All references cited herein, including publications, patents and patent applications, are incorporated herein by reference in their entirety.
[0224] The term "antigen" as used herein refers to a molecule that causes an immune response, which may involve antibody production, or the activation of specific immunocompetent cells. It will be appreciated by those skilled in the art that any macromolecule, including all proteins or peptides, can be used as an antigen. Antigens may be derived from recombinant or genomic DNA. It will be appreciated by those skilled in the art that any DNA, including a nucleotide sequence or a partial nucleotide sequence encoding a protein that causes an immune response, encodes the term "antigen" as used herein. In addition, it will be appreciated by those skilled in the art that an antigen need not be encoded solely by the full-length nucleotide sequence of a gene. It is readily apparent that the present disclosure includes, but is not limited to, the use of partial nucleotide sequences of more than one gene, and that these nucleotide sequences are arranged in different combinations to cause a desired immune response. The "polypeptide" in the present application comprises one or more antigen fragments selected from the following consisting of 10-50, such as 20 to 50, or 25-30 amino acids: ACTL8, BRDT, FOXI3, GNGT1, SMC1B, PLAC1, MAGEA1, MAGEA3, MAGEA4, MAGEA6, MAGEA10, MAGEA11, TP53.175R / H, TP53.220Y / C, PIK3CA.545E / K and KRAS.12G / D, wherein the one or more antigen fragments are connected by a connecting peptide, and the antigen fragment contains one or more antigen epitope peptides. In some embodiments, the antigen fragment comprises an amino acid sequence selected from SEQ ID NOs: 108-162; in some embodiments, the polypeptide comprises 20 antigen fragments, each of which is selected from the amino acid sequence shown in SEQ ID NOs: 108-127; in some embodiments, the polypeptide comprises 20 antigen fragments, each of which is selected from the amino acid sequence shown in SEQ ID NOs: 128-147; in some embodiments, the polypeptide comprises 15 antigen fragments, each of which is selected from the amino acid sequence shown in SEQ ID NOs: 148-162. In addition, it is understood by those skilled in the art that antigens do not have to be encoded by "genes" at all, and antigens can be produced, synthesized, or can be derived from biological samples. Such biological samples can include, but are not limited to, tissue samples, tumor samples, cells, or biological fluids.
[0225] The term "epitope peptide" used herein refers to a polypeptide molecule in an antigen molecule that determines the antigen specificity. Antigens bind to antigen receptors on the surface of corresponding lymphocytes through antigen epitopes, thereby activating lymphocytes and causing immune responses; antigens also exert immune effects by specifically binding to corresponding antibodies or sensitized lymphocytes through epitopes. The size of the antigen epitope is suitable for the antigen binding site of the corresponding antibody. The specificity of an antigen epitope is determined by all the residues that make it up, but some of the residues play a greater role than other residues when binding to antibodies. The "epitope peptide" of the present invention refers to a polypeptide molecule containing 6-13, such as 8-13, or 8-9 amino acid residues that targets ACTL8, BRDT, FOXI3, GNGT1, SMC1B, PLAC1, MAGEA1, MAGEA3, MAGEA4, MAGEA6, MAGEA10 and MAGEA11 antigens. In some embodiments, the antigen epitope peptide comprises an amino acid sequence selected from SEQ ID NOs: 1-107 or SEQ ID NOs: 163-225.
[0226] Unless otherwise specified, the nucleotide sequence "encoding" a nucleic acid molecule of a protein or an amino acid sequence of a protein used herein includes all nucleotide sequences that are degenerate and encode the same amino acid sequence. The nucleotide sequence may also include one or more introns.
[0227] As used herein, the term "subject" includes any human or non-human animal. The term "non-human animal" includes all vertebrates, such as mammals and non-mammals, such as non-human primates, sheep, dogs, cats, horses, cows, chickens, rats, mice, amphibians, reptiles, etc. Unless otherwise indicated, the terms "patient" or "subject" are used interchangeably. In the present disclosure, the preferred subject is a human.
[0228] As used herein, the term "treatment" refers to administering to a subject an effective amount of a polypeptide or vaccine as described herein, so that the subject has a reduction in at least one symptom of the disease or an improvement in the disease, for example, a beneficial or desired clinical outcome. For the purposes of this disclosure, beneficial or desired clinical outcomes include, but are not limited to, alleviation of one or more symptoms, reduction in the extent of the disease, stabilization of the disease state (i.e., no worsening), delay or slowing of disease progression, improvement or alleviation of the disease state, and relief (whether partial or total relief), whether detectable or undetectable. Treatment may refer to prolonging survival compared to the expected survival without treatment. Therefore, those skilled in the art recognize that treatment may improve the disease condition, but may not be a complete cure for the disease. As used herein, the term "treatment" includes prevention. Alternatively, treatment is "effective" in the case of a reduction or cessation of disease progression. "Treatment" may also mean prolonging survival compared to the expected survival without treatment. Patients in need of treatment include those who have been diagnosed with a disease associated with the expression of a polynucleotide sequence, and those who may develop such a disease due to genetic susceptibility or other factors.
[0229] The term "disease" includes breast cancer, colon cancer, rectal cancer, esophageal cancer, lung cancer, liver cancer, gastric cancer, non-small cell lung cancer, squamous cell carcinoma, adrenal cancer, melanoma, and ovarian cancer. Preferably, the disease is selected from esophageal squamous cell carcinoma, lung squamous cell carcinoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, gastric cancer, lung adenocarcinoma, colon cancer and rectal cancer, and oral squamous cell carcinoma.
[0230] Example
[0231] In order to enable those skilled in the art to better understand the solutions of the present disclosure, the technical solutions in the embodiments of the present disclosure will be clearly and completely described below. Obviously, the described embodiments are only part of the embodiments of the present disclosure, rather than all of the embodiments.
[0232] Example 1: Antigen target screening
[0233] The screening process of esophageal squamous cell carcinoma antigen targets and epitopes is as follows Figure 1 As shown, in order to screen tumor antigen targets that meet the expression characteristics of esophageal squamous cell carcinoma (ESCC) population, this paper analyzed 80 ESCC tumor tissue RNAseq data (derived from TCGA) and 555 esophageal mucosal tissue RNAseq data (derived from GTEx), and set the following antigen screening rules:
[0234] (1) The expression of the selected genes was significantly upregulated in esophageal squamous cell carcinoma compared with that in normal esophageal mucosal tissue. DESeq2 (R package v1.38.3) was used to analyze the differential expression of genes in the tumor group and the normal group. The Benjamini-Hochberg method was used to adjust the p value to reduce the false discovery rate. The screening criteria for differentially expressed genes: the corrected P value was less than 0.01, and |log2(fold-change)|>1);
[0235] (2) The average TPM value of 50 normal human tissues except testis and uterus was less than 0.25;
[0236] (3) In the TCGA ESCC cohort, the number of samples with TPM greater than 1 exceeded 20%.
[0237] The results of bioinformatics analysis are shown in Figure 2. Through differential gene expression screening, 4478 genes upregulated in esophageal squamous cell carcinoma were found. After excluding normal tissue expression and ensuring that it has a certain coverage in tumor patients, 27 genes can be screened. After completing the investigation of the protein functions translated by the 27 genes, 12 candidate antigens with the best therapeutic potential were selected to enter the experimental verification stage, namely ACTL8, BRDT, FOXI3, GNGT1, SMC1B, PLAC1, MAGEA1, MAGEA3, MAGEA4, MAGEA6, MAGEA10 and MAGEA11.
[0238] Example 2: Expression analysis of candidate antigens in other tumor types
[0239] Based on the RNAseq sequencing data of patients in the TCGA database, bioinformatics analysis was performed on the expression of the 12 candidate antigens selected in Example 1 in hepatocellular carcinoma, gastric cancer, lung adenocarcinoma, lung squamous cell carcinoma, colon cancer and rectal cancer. The median value of the TPM (transcripts per million) of the gene in normal tissues in the GTEx database was used as the cutoff value. If the TPM of the gene in the tumor sample was greater than the cutoff value, it was considered that the patient expressed the gene. The ratio of the number of patients expressing the gene to the total number of patients with the cancer was calculated. The results are shown in the figure. Figure 3 The results showed that the 12 selected candidate antigens were expressed in different proportions in the above different tumor types.
[0240] Example 3: Coverage verification of candidate antigens in clinical samples
[0241] In order to verify the coverage of the selected antigens in patients, we collected and sequenced 132 tumor tissues and 96 adjacent tissues provided by Peking University Cancer Hospital. After the samples were qualified, 1 to 3 ug of total RNA was taken from each sample as the starting material to construct the transcriptome sequencing library. According to the VAHTS Universal V6 RNA-seq LibraryPrep Kit for (NR604-01 / 02) operating instructions, select different index tags to build libraries. For qualified total RNA samples, Oligo (dT) magnetic beads are used to enrich mRNA with polyA tails, and then fragmentation buffer is added to break the mRNA into short fragments. The first chain of cDNA is synthesized with random hexamers using mRNA as a template, and then RNaseH is used to degrade the RNA template chain, and dNTPs are used as raw materials to synthesize the second chain of cDNA under the DNA polymerase I system, and then AMPure Pbeads purification or QiaQuick PCR kit is used to purify double-stranded cDNA. The purified double-stranded cDNA is repaired at the end, A-tailed and connected to the sequencing adapter, and then the fragment size is selected, and finally PCR amplification is performed to obtain the final cDNA library. After the library inspection is qualified, the samples are mixed and pooled according to the effective concentration of the library and the target required data volume, and the Illumina platform is used for sequencing. The PE150 sequencing strategy is run to obtain a double-end sequencing read length of 150bp. The basic principle of sequencing is sequencing by synthesis. Four fluorescently labeled dNTPs, DNA polymerase and adapter primers are added to the sequencing flow cell for amplification. When each sequencing cluster extends the complementary chain, each fluorescently labeled dNTP added can release the corresponding fluorescence. The sequencer captures the fluorescent signal and converts the light signal into a sequencing peak through the computer software bcl2fastq, thereby obtaining the sequence information of the fragment to be tested and storing it in the FASTQ file format. Next, the fast-0.22.0 software (https: / / github.com / OpenGene / fastp) is used to filter the raw data, and clean data is obtained after removing the adapter sequence, removing the read length with a high proportion of N (N means that the base information cannot be determined), and removing the low-quality sequence. Clean Data after rRNA removal was aligned to the reference genome (GRCh38) using STAR-2.7.10b (https: / / github.com / alexdobin / STAR / ). Next, featureCounts v2.0.3 software was used to quantify gene expression in each sample. The criterion for high antigen expression was that the TPM of the gene in the tumor sample was greater than the mean plus standard deviation of the TPM of the gene in 96 adjacent adjacent samples.The tumor tissue of each patient carries at least 2 antigen target RNAs with high expression, nearly 90% of the patients carry at least 5 antigen targets with high expression, and the proportion of patients carrying 8 or more antigen targets is as high as 53.79%. The results are as follows. Figure 4 shown.
[0242] Example 4: Epitope screening of candidate antigens
[0243] HLA-A*02:01 and HLA-A*11:01 are the two HLA subtypes with the highest coverage frequency in the world. The European and American population is mainly composed of the HLA-A*02:01 subtype, while the Chinese population is mainly composed of the HLA-A*11:01 subtype. Taking into account the influence of HLA biallelic genes, these two HLAs can cover more than half of the total population. Therefore, the present disclosure uses K562 cell lines that only express a single HLA-A2.1 or HLA-A11.1 as genetically engineered antigen-presenting cells for these two HLA subtypes, and electrophoretically transfects plasmids expressing the above 12 TAAs, respectively, and separates the HLA-presented polypeptides by immunoprecipitation after lysing the cells, and performs mass spectrometry detection. The experimental process is as follows:
[0244] 1. Cell Preparation
[0245] K562 cells (purchased from Zhejiang Meisen) were revived and cultured according to the instructions, and K562-HLA-A2.1 and K562-HLA-A11.1 cells were prepared by transfecting HLA-A2.1 and HLA-A11.1 genes (the method refers to Eichmann, Metal. Tissue antigens vol. 84, 4 (2014): 378-88).
[0246] 2. Electroporation of overexpression plasmid
[0247] According to the information of 12 antigens (Uniprot ID: Q9H568, Q58F21, A8MTJ6, P63211, P43363, P43364, P43355, P43357, P43358, P43360, Q9HBJ0, Q8NDV3), an overexpression vector (synthesized by Nanjing GenScript) was constructed with pcDNA3.1(+) as the backbone. 7 Cells were divided into 1.5 mL centrifuge tubes. After centrifugation, the cell pellets were collected and washed twice with PBS. After washing, the supernatant should be fully removed before preparing the electroporation system. The electroporation operation steps refer to the Neon TM 100μL Electrotransfer Kit Operating Instructions. After electrotransfer, the cells were quickly transferred to a T175 bottle and cultured in a 37°C, 5% CO2 incubator for 24 hours before the cells were harvested for mass spectrometry sample preparation.
[0248] 3. Mass Spectrometry Sample Preparation
[0249] Mass spectrometry samples were prepared according to the experimental process (Purcell, Anthony W et al. Nature protocols vol. 14, 6 (2019): 1687-1707). First, each group of K562-HLA cells was transferred to a 50 mL centrifuge tube, centrifuged at 1500 rpm for 10 minutes at room temperature, and resuspended in 5 mL PBS for counting. The cells were divided into 1.5 mL centrifuge tubes according to the counting results, with 2 × 10 cells in each tube. 7 , centrifuge to collect cells; discard the supernatant, add 1mL of pre-cooled PBS to each tube, centrifuge at 1500rpm for 5 minutes at room temperature, discard the supernatant, and repeat washing once. Then, prepare the cell lysis solution in advance, add 1mL of cell lysis solution to each tube of cell pellet, fully resuspend the cell pellet, place the EP tube on a test tube rotating shaker, 4℃, lyse for 30 minutes; after lysis, centrifuge at 4℃, 12000rpm for 20 minutes, and collect the supernatant. After that, add 40μL of affinity gel to the supernatant of the cell lysate collected in each tube in the previous step, mix well, place the tube on a rotating shaker, 4℃, incubate for 3 hours; after incubation, set the centrifuge program at 4℃, 14000rpm for 1 minute, and remove the supernatant. Finally, add 1mL of ice-cold washing solution to the pellet, mix well, centrifuge at 4℃, 14000rpm for 1 minute, and repeat washing 4 times. After the last wash, remove the supernatant thoroughly, add 40 μL of acetic acid eluent to the precipitation tube and mix thoroughly, incubate at 65°C for 15 minutes and then return to room temperature; balance the sample and place it in a centrifuge, set the centrifugation program at 4°C, centrifuge at 14000rpm for 1 minute, carefully collect all the sample supernatant and transfer it to a new 1.5ml EP tube for storage.
[0250] 4. Mass spectrometry detection
[0251] The prepared samples were sent to Baizhen Biotechnology Co., Ltd. for mass spectrometry detection. The mass spectrometry detection results obtained in this experiment were statistically analyzed to compare the differences in the number of immune peptides matching the target protein.
[0252] Based on mass spectrometry detection, combined with NetMHCPan 4.1BA prediction, IEDB database and literature search, the epitope library of the above 12 candidate antigens was obtained, among which the newly discovered HLA-A2.1 and HLA-A11.1 epitopes are shown in Tables 1 and 2.
[0253] Table 1. Antigen HLA-A2.1 epitopes
[0254]
[0255]
[0256] Table 2. Antigen HLA-A11.1 epitopes
[0257]
[0258]
[0259]
[0260] Example 5: Antigen epitope affinity verification
[0261] In order to compare the relative affinity of each antigen peptide in the epitope peptide library, cELISA and cell-loaded peptide were used to identify the affinity of each antigen peptide. The cELISA test process is as follows:
[0262] Preparation before experiment: 1) Peptide Flex-T TM Monomer UVX cannot be repeatedly frozen and thawed, so for the first use, it should be aliquoted and labeled with the name and aliquot date and stored at -20°C. For subsequent use, take the aliquot tube and use it directly; 2) LEGENDMAX TM Flex-T TM Take out the Human Class IPeptide Exchange ELISA Kit in advance and restore it to room temperature.
[0263] Antigen peptide replacement: Take out the reagents required for the experiment and place them in an ice bath; dilute the peptide to 400 μM with PBS (if DMSO is required for dissolution, the concentration of DMSO cannot exceed 10% (v / v)), place it in an ice bath for later use; take a 96-well plate with V-shaped holes, and use a pipette to add 20 μL of the diluted antigen peptide and 20 μL of peptide Flex-T into the well. TM monomer UVX (200μg / mL), blank control (UV only) group is 20μL PBS and 20μL peptide Flex-T TM Monomer UVX (200μg / mL) was mixed by pipetting; capped, centrifuged at 2500g for 2 minutes at 4℃ to allow the liquid to sink to the bottom of the well; removed the cap, and placed the 96-well plate in an ice bath under a UV lamp (366nm): irradiated for 30 minutes, with a sample-lamp distance of 2-5cm. #Biolegend recommends using 8W, 366nm UV; capped, and incubated the well plate at 37℃, away from light, for 30 minutes to allow the antigen peptide to fully bind; centrifuged, and the liquid in the well was collected for use. (The liquid contains the prepared pMHC monomer complex, and the concentration of the pMHC monomer complex in each well is 100μg / mL).
[0264] Peptide displacement activity detection: dilute 20×Wash Buffer to 1×Wash Buffer with ddH2O; dilute the prepared pMHC complex sample to 5ng / mL with AssayBuffer A, which is the monomer complex sample working solution; take out the required reagents and restore to room temperature, take out the required ELISA strips and put them into the ELISA plate; first add 50μL of Assay Buffer A to the wells of the ELISA plate, and then continue to add 50μL of sample solution (the sample concentration after this step is 2.5ng / mL, and each sample has 2 replicate wells) or control solution (Assay Buffer A) to the corresponding wells. Seal the ELISA plate with a sealing film and shake it on a shaker at room temperature for 30 minutes (220rpm can be selected); discard the liquid in the wells and wash the plate 4 times with 200μL 1×Wash Buffer / well. Try to control the liquid as much as possible each time you discard the liquid. You can turn the plate upside down on absorbent paper laid flat on the table to absorb the liquid.
[0265] After draining the liquid, add 100 μL of avidin-HRP reagent to each well, seal with sealing film, and incubate on a shaker at room temperature for 30 minutes (220 rpm can be selected); discard the liquid in the well, and wash the plate 5 times according to the above washing steps. After adding Wash Buffer for the last time, let the liquid soak in the well for 30 seconds to 1 minute to minimize background interference;
[0266] After the liquid is dried in the last step, add 100 μL of substrate solution F to each well and incubate in the dark at room temperature for 10 minutes; (the color of the liquid in the experimental well should turn blue after the addition of the substrate, and the blue color gradually deepens as the sample concentration increases; this step can be selectively sealed and incubated); after the incubation, add 100 μL of stop solution to each well (the color of the liquid turns from blue to yellow after the addition of the stop solution); after the color development is stopped, use an enzyme reader to detect the absorbance values of the two bands of OD450 and OD570 within 30 minutes.
[0267] Data processing, the calculation formula is as follows:
[0268]
[0269] The cell loading peptide method is as follows (refer to patent, application number 202410069100.3):
[0270] Cell plating: Take an appropriate amount of K562-HLA-A*11:01-TAP_KO / K562-HLA-A*02:01-TAP_KO- cells, resuspend the cells in 1 ml serum-free RPMI 1640 medium and count the cells. Adjust the cell concentration to 1×10 6 / ml, 100 μl / well was inoculated in a 48-well plate, that is, the number of cells in each well was 1×105 β2M protein (final concentration 5 μg / ml) and antigen peptide (final concentration 60 μM) were added and incubated overnight in a carbon dioxide incubator.
[0271] Flow cytometry: The next day, collect cells into flow tubes, centrifuge at 350×g for 5 minutes, and discard the supernatant. Wash cells twice with 2ml PBS, centrifuge at 350×g for 5 minutes at room temperature, discard the supernatant, and resuspend cells in 100μl PBS. Add 2μl BV510 anti-human HLA-ABC to each tube, incubate at room temperature in the dark for 20 minutes, wash cells once with 2ml PBS, centrifuge at 350×g for 5 minutes at room temperature, discard the supernatant, and resuspend cells in 200μl PBS. Use flow cytometry to detect the expression level of HLA-ABC molecules on the surface of K562 cells.
[0272] Data processing: MFI Ratio = (MFI test group - MFI control group) / (MFI positive peptide group - MFI control group)
[0273] For the epitope with relatively high mass spectrometry detection intensity in Example 4, the corresponding peptide was synthesized (synthesized by Nanjing GenScript) and affinity tested. The cELISA test results of the antigen HLA-A2.1 epitope peptide are shown in Figure 5 , cell loading peptide results are shown in Figure 6 ; The cELISA test results of antigen HLA-A11.1 epitope peptide are shown in Figure 7 , cell loading peptide results are shown in Figure 8 . The criteria for affinity determination based on cElisa and cell-loaded peptide tests are as follows: Strong positive: the ratio of the test to positive (cElisa) or the MFI ratio (cell-loaded peptide) is greater than 1. Moderate positive: the ratio of the test to positive (cElisa) or the MFI ratio (cell-loaded peptide) is greater than the middle value of the positive and negative control peptides, and less than 1. Weak positive: the ratio of the test to positive (cElisa) or the MFI ratio (cell-loaded peptide) is less than the middle value of the positive and negative control peptides, greater than the negative control peptide, and less than the negative control peptide, which is considered negative. Detailed results are shown in Tables 3, 4, 5, and 6.
[0274] Table 3. HLA-A2.1 epitope peptide cElisa test results
[0275]
[0276]
[0277] Table 4. Results of HLA-A2.1 epitope peptide cell loading peptide detection
[0278] SEQ ID NO Amino acid sequence K562 loaded peptide 1 ALDESNTYQL Weak Yang 5 AGWNEPQMV Weak Yang 7 YASGLLTGV Weak Yang 8 EMFPKFTEV Strong Yang 9 RLLDVNNQL Zhongyang 11 ATEKVFKQ Weak Yang 12 TLSHIYQ Weak Yang 13 KLKMEVDQL Weak Yang 14 LIYGEPRKL Weak Yang 16 ALAETSYV Weak Yang 17 VLEYVIKV Zhongyang 20 ALAETSYV Weak Yang 23 SIDWFMVTV Weak Yang 25 KLQKEVVSI Zhongyang 26 KVFGRFITA Strong Yang 27 RALENLKTV Weak Yang 28 RMSEFNEEL Weak Yang
[0279] Table 5. HLA-A11.1 epitope peptide cElisa test results
[0280]
[0281]
[0282] Table 6. Results of HLA-A11.1 epitope peptide cell loading peptide detection
[0283]
[0284]
[0285] Example 6: ECVAC vaccine design
[0286] Three vaccines were designed for different HLA populations based on the epitope information of 12 antigens. ECVAC-A2 is designed for the HLA-A*02:01 population. 18 25 amino acid fragments are selected from the above 12 antigens and two common new antigen fragments TP53.175R / H and TP53.220Y / C (Table 7) in tumor patients to form a tandem sequence of 20 antigen fragments. Each fragment contains at least one HLA-A*02:01 epitope, and some fragments can contain multiple antigen epitopes at the same time, including a total of 50 identified HLA-A*02:01 epitopes, see Table 8 for details. ECVAC-A11 is designed for the HLA-A*11:01 population. 18 25 amino acid fragments are selected from the above 11 antigens (except PLAC1) and two common new antigen fragments PIK3CA.545E / K and KRAS.12G / D in tumor patients to form a tandem sequence of 20 antigen fragments. Each fragment contains at least one HLA-A*11:01 epitope, and a total of 30 HLA-A*11:01 epitopes have been identified. For details, see Table 9. ECVAC-A2 / 11 is designed to take into account both HLA-A*02:01 and HLA-A*11:01 populations. A total of 15 fragments with a length of 30 amino acids were selected from 9 antigens (except PLAC1, FOXI3, and MAGEA10). Each fragment contains at least one HLA-A*02:01 and HLA-A*11:01 epitope. The 15 antigen fragments contain a total of 46 HLA-A*02:01 epitopes and 37 HLA-A*11:01 epitopes that have been identified. For details, see Tables 10 and 11.
[0287] In order to avoid the generation of new epitopes by connecting different antigen fragments, different fragments were connected with non-immunogenic GS linker, and then the universal Th cell epitope PADRE was introduced to ensure high population response rate and sufficient immunogenicity. At the same time, HLA-I signal peptide (SP) and transmembrane / intracellular segment MITD (MHC class I trafficking signal domain) structure were added at the N-terminus and C-terminus respectively to enhance the efficiency of overall antigen presentation. Finally, the amino acid sequence of each vaccine was obtained, see the sequence table. Taking ECVAC-A2 / 11 as an example, the structure is shown in Fig. 9 .
[0288] Table 7. Antigenic fragments corresponding to ECVAC-A2, ECVAC-A11 and ECVAC-A2 / 11
[0289]
[0290]
[0291] Table 8. HLA-A*02:01 epitopes of ECVAC-A2
[0292]
[0293]
[0294] Table 9. HLA-A*11:01 epitopes of ECVAC-A11
[0295]
[0296] Table 10. HLA-A*02:01 epitopes of ECVAC-A2 / 11
[0297]
[0298]
[0299] Table 11. HLA-A*11:01 epitopes of ECVAC-A2 / 11
[0300]
[0301]
[0302] Table 12. Antigen polypeptide sequences
[0303]
[0304]
[0305] Table 13. Amino acid sequence
[0306]
[0307]
[0308] Example 7: mRNA sequence optimization
[0309] Sequence optimization of the CDS region of vaccine mRNA can improve its translation efficiency, and structural optimization can improve its half-life. The general principle of CDS sequence optimization is to use the degeneracy of codons to find stable and high-yield mRNA sequences to increase the expression of functional proteins. The codon adaptation index (CAI) refers to the degree of consistency between the codon usage frequency of the heterologous mRNA sequence and the optimal codon usage frequency of the host cell. Replacing the codons in the exogenous mRNA sequence with synonymous codons with high usage frequency in the host cell can ensure that the codon usage bias of the codons in the exogenous mRNA sequence and the host cell is more consistent, which can significantly improve the translation efficiency of mRNA. In addition, GC-rich mRNA can be transcribed or processed more efficiently, thereby producing more mRNA in a stable state. Therefore, when selecting codons, it is also necessary to increase the GC content as much as possible to further improve the stability and translation efficiency of mRNA. In addition, CDS optimization also needs to consider the stability of the mRNA secondary structure, reduce its minimum folding free energy (MFE), and increase the half-life of mRNA in vivo, so that it can express more functional proteins. Of course, the standards for processing different functional regions are also different. For example, the fewer secondary structures formed by the first ten codons in the mRNA CDS region, the higher the expression level of the protein it encodes; the more secondary structures formed by the remaining CDS region, the higher the expression level of the protein it encodes.
[0310] Therefore, the present invention optimizes the sequences of ECVAC-A2, ECVAC-A11 and ECVAC-A2 / 11 according to the above principles, and comprehensively considers the influence of various factors to select 6-7 sequences for each vaccine for experimental verification. The sequences are shown in Table 14.
[0311] Table 14. Optimized nucleic acid sequences
[0312]
[0313]
[0314]
[0315]
[0316]
[0317]
[0318]
[0319]
[0320]
[0321]
[0322]
[0323] Example 8: In vitro screening of optimized mRNA sequences
[0324] In order to find three ECVAC mRNA sequences with better functionality for different HLA versions, 6-7 mRNA sequences were designed for ECVAC-A2, ECVAC-A11 and ECVAC-A2 / 11 respectively through optimization in terms of GC content, CAI and MFE. In this example, the optimal sequence was screened in multiple dimensions based on the test results such as mRNA electrophoretic mobility, mRNA integrity, mRNA intracellular degradation ability and mRNA in vitro protein translation level, and the three most comprehensive sequences were selected for each version, and a total of 9 mRNAs were used for subsequent in vivo immunogenicity verification in HLA transgenic (transgene, Tg) mice.
[0325] The nucleic acid sequences of ECVAC-A2, ECVAC-A11 and ECVAC-A2 / 11 mRNA are shown in Table 14. The mRNA production was carried out according to the instructions of T7 High Yield RNA Transcription Kit (Novozymes, TR101-02).
[0326] 1. Detection of mRNA mobility by non-denaturing gel electrophoresis
[0327] Electrophoretic mobility tests were performed on each prepared mRNA using 1% non-denaturing agarose gel. In theory, mRNA molecules with lower MFE (MFE: minimum free energy) values have more compact shapes and smaller kinetic sizes. Since the more stable the secondary structure of mRNA, the faster the electrophoretic migration, different mRNA sequences designed based on theoretical MFE can be screened and verified through experiments. The results are shown in Figure 2. Fig.10As shown: the migration rates of each version of mRNA are somewhat different, and they are all correlated with their theoretical MFE values. After statistical analysis of the electrophoretic migration results, it can be concluded that among the 7 mRNAs in the ECVAC-A2 / 11 group, ECVAC-A2 / 11-V1.2 migrates the fastest, among the 7 mRNAs in the ECVAC-A2 group, ECVAC-A2-V1.1 migrates faster, and among the 6 mRNAs in the ECVAC-A11 group, ECVAC-A2-V1.2 migrates faster, which is consistent with the theoretical value. In summary, the results of non-denaturing gel electrophoresis can preliminarily indicate a more stable mRNA version.
[0328] 2. qPCR detection of mRNA intracellular degradation
[0329] The intracellular expression level of mRNA (mRNA half-life) was used as another indicator for screening mRNA stability. K562 cells (purchased from Zhejiang Meisen) were selected as test cells. 6-7 mRNAs of each type A2, A11, and A2 / 11 were transfected, and the electroporated K562 cell samples were collected at different time points of 0, 3, 6, 12, 24, and 48 hours. The amplification primers were set as UTR-F3 (GTTCCAGACACCTCCCAAGC) and UTR-R3 (TGTGGCTGGCACGAAATTGA) for RNA extraction and qPCR detection. The qPCR results were analyzed. -ΔCT The vertical axis is the transfection time, and the intracellular degradation of different versions of mRNA within 48 hours is compared. Fig.11 As shown: Within a certain time range, each version of mRNA shows different degradation conditions in the cell. By comparing the Half-life values obtained from the three groups of mRNA ECVAC-A2 / 11, ECVAC-A2, and ECVAC-A11, it can be concluded that the three mRNA versions with longer half-lives are: ECVAC-A2 / 11 (V1.2, V1.3, V1.4); ECVAC-A2 (V1.2, V1.3, V1.6); ECVAC-A11 (V1.2, V1.3, V1.5), which can be used as reference indicators for subsequent determination of the optimal sequence.
[0330] 3. Cell free system to detect mRNA translation level
[0331] ECVAC mRNA is a series of tandem antigen epitopes. It lacks relevant detection antibodies and cannot be detected by traditional cell transfection methods using Western-blot. The application of the cell free reaction system (Rabbit Reticulocyte Lysate System, Promega, L4960) can realize the process of mRNA translation and protein synthesis in an in vitro cell-free system. In this experiment, rabbit reticulocytes were used to optimize biotin-coupled tRNA (Transcend TM Non-Radioactive Translation Detection System, Promega, L5061), labeled lysine, and directly detected the synthesized protein in vitro, avoiding the limitation of lack of antibodies. Therefore, the present disclosure uses this system to complete subsequent experiments. However, the system also has certain limitations: the system is a rabbit-derived translation system, and ECVAC mRNA is a sequence after humanized codon optimization, which may have the risk of low translation efficiency; the detection intensity of the system is theoretically related to the proportion of lysine contained in the sequence, but because the lysine content in the ECVAC mRNA sequence is basically the same, this method is chosen to detect the mRNA translation efficiency after comprehensive consideration. Therefore, in order to compare the in vitro translation levels of different versions of mRNA, a cell free system was prepared to translate mRNA in vitro, and Western Blot experiment was used to detect protein expression levels. The results are shown in Fig.12 As shown: ECVAC-A2 (V1.0, V1.3, V1.5, V1.6), ECVAC-A11 (V1.0, V1.3, V1.5), and ECVAC-A2 / 11 (V1.1, V1.2, V1.4, V1.5, and V1.6) were all detected to have in vitro expression; after quantitative statistics of the obtained bands, it was concluded that the three versions with higher mRNA expression levels were: ECVAC-A2 (V1.0, V1.3, V1.5), ECVAC-A11 (V1.0, V1.3, V1.5), and ECVAC-A2 / 11 (V1.2, V1.4, V1.5).
[0332] 4. ECVAC optimization sequence determination
[0333] Through optimization in terms of GC content, CAI and MFE, there are certain differences in the functions of various versions of ECVAC mRNA. The statistical results are shown in Table 15. This experiment focuses on screening the stability of mRNA from three aspects: mRNA intracellular degradation level, in vitro expression level and mobility, and selecting the most stable version from each group of mRNA. That is, the following optimal mRNA sequences (ECVAC-A2-1.0, ECVAC-A2-1.3, ECVAC-A2-1.5, ECVAC-A2 / 11-1.2, ECVAC-A2 / 11-1.4, ECVAC-A2 / 11-1.5, ECVAC-A11-1.0, ECVAC-A11-1.3, ECVAC-A11-1.5) were determined from the three groups of mRNA ECVAC-A2, ECVAC-A2 / 11 and ECVAC-A11 as the objects of subsequent in vivo immunogenicity verification in Tg mice.
[0334] Table 15. Statistics of mRNA intracellular half-life, in vitro expression level and mobility
[0335]
[0336] Example 9: In vivo screening of mRNA optimized sequences
[0337] In vivo tests in animals can better simulate the actual effects of drugs in clinical practice. Therefore, the present invention further compares the immunogenicity of three optimized sequences selected from the three groups of ECVAC-A2, ECVAC-A11, and ECVAC-A2 / 11 in vitro tests in HLA transgenic mice to determine the one with the strongest immunogenicity as the final drug candidate molecule.
[0338] This study used two HLA transgenic mice (HLA-A2.1 and HLA-A11.1) (purchased from Biocytogen, catalog numbers 110110 and 112803), 5 mice in each group, and immunized with the mRNA-LNP vaccine to be screened by intramuscular injection, once every 7 days, for a total of 3 times. Three days after the third immunization, the spleen of the mice was taken and the best immunogenic drug candidate molecules were screened by ELISPOT method.
[0339] mRNA LNP preparation: The preparation equipment used was a microfluidic nanoparticle preparation instrument (Ignite, PNI), and the preparation parameters were referred to the equipment manual. The lipids (LNP) used were the same as those used in the vaccine BNT162b2 produced by Pfizer / BioNtech, namely ALC-0315, ALC-0159, DSPC, and cholesterol.
[0340] Dosage regimen
[0341] In two different HLA transgenic animals, the principles of group design are consistent. G1 is a solvent control, G2, G3, and G4 are tumor vaccines with single HLA epitopes of HLA-A2.1 or HLA-A11.1, and G5, G6, and G7 are tumor vaccines with dual HLA epitopes of HLA-A2.1 and HLA-A11.1. The specific dosing regimens are shown in Tables 16 and 17.
[0342] Table 16. HLA-A2.1 Animal Dosing Schedule
[0343]
[0344] Note: im: intramuscular injection, the injection site is the bilateral thigh muscles; the test article is prepared at a concentration of 40μg / mL for administration.
[0345] Table 17. Dosing schedule for HLA-A11.1 animals
[0346]
[0347] Note: im: intramuscular injection, the injection site is the bilateral thigh muscles; the test article is prepared at a concentration of 40μg / mL for administration.
[0348] When implementing ELISPOT, two peptide libraries of different lengths are used to stimulate T cells, namely the epitope (short) peptide library and the scanning (long) peptide library. The epitope peptides selected are the epitope peptides that are most likely to be presented by HLA in each antigen fragment of ECVAC-A2, ECVAC-A11, and ECVAC-A2 / 11. Every 5 epitope peptides form a peptide library (P1-P4). The long peptide library is composed of 15 amino acid scanning peptides. The scanning peptides cover the entire sequence of an antigen fragment, and there is a 10 amino acid sequence overlap between two adjacent scanning peptides. Every 5 antigen scanning peptides form a peptide library (LP1-LP4). The scanning peptide library can avoid missing immune responses other than the selected epitope during detection.
[0349] 1. In vivo screening of optimized ECVAC-A2 sequences
[0350] The frequency of antigen-specific T cells of HLA-A2.1 mouse single HLA epitope vaccine is summarized in Table 18. The data were analyzed using IBM SPSS Statistics 25.0 statistical software, and the mean values of the detection data of different peptide libraries were compared between groups by One-Way ANOVA test; Graphpad Prism 8 software was used to perform overall comparisons between groups by Two-Way ANOVA test, and p < 0.05 was considered to be significantly different. The statistical analysis results are detailed in Table 19. Data display is shown in Fig.13 .
[0351] Table 18. Summary of the frequency of antigen-specific T cells in HLA-A2.1 mouse single HLA epitope vaccine (Mean±SD) Unit: SFU / 2*10^5 cells
[0352] Peptide library G1 G2 G3 G4 A2-P1 2±2 148±42 64±75 21±12 A2-P2 2±1 217±119 242±225 137±81 A2-P3 1±1 12±15 7±8 6±2 A2-P4 3±1 984±194 1449±321 1008±256 A2-LP1 3±2 104±55 26±18 13±6 A2-LP2 2±1 90±33 82±78 89±73 A2-LP3 4±2 117±59 139±46 126±72 A2-LP4 1±1 919±166 1428±413 960±258
[0353] Table 19. Summary table of p-values of the frequency of antigen-specific T cells in HLA-A2.1 mouse single HLA epitope vaccine
[0354] Peptide library <![CDATA[G3 p a ]]> <![CDATA[G4 p a ]]> <![CDATA[G4 p b ]]> A2-P1 0.023* 0.002** 0.197 A2-P2 0.797 0.430 0.301 A2-P3 0.429 0.333 0.853 A2-P4 0.016* 0.891 0.021* A2-LP1 0.066 0.043* 0.336 A2-LP2 0.856 0.992 0.863 A2-LP3 0.57 0.817 0.734 A2-LP4 0.019* 0.83 0.028* Overall comparison 0.008** 0.684 <0.001***
[0355] Note: p in p value a Compared with G2 group, p b For comparison with the G3 group; * , p<0.05; ** , p<0.01; *** , p<0.001.
[0356] The experimental results showed that the antigenic epitopes in the No. 4 peptide library (including short peptides and / or long peptides) contained the most dominant antigenic epitopes that stimulated HLA-A2.1 transgenic mice after vaccine immunization, and positive reactions were also detected in the No. 1, No. 2, and No. 3 peptide libraries (including short peptides and / or long peptides). After stimulation with the No. 1 peptide library, the frequency of antigen-specific T cells in the spleen cells of mice in the G2 group was higher than that in the G3 and G4 groups, and the G2 group was significantly higher than the G4 group after P1 and LP1 stimulation (p<0.05), and the G2 group was significantly higher than the G3 group after P1 stimulation. After stimulation with the No. 4 peptide library, the frequency of antigen-specific T cells in the spleen cells of mice in the G3 group was significantly higher than that in the G2 and G4 groups after P4 and LP4 stimulation. There was no significant difference between the three groups in the stimulation of the No. 2 and No. 3 peptide libraries. Using different peptide libraries as analysis factors, an overall intergroup comparison was performed on the three groups. The G3 (ECVAC-A2-1.3) group was significantly superior to the G2 and G4 groups, and there was no significant difference between the G2 and G4 groups.
[0357] 2. In vivo screening of optimized ECVAC-A11 sequences
[0358] The frequency of antigen-specific T cells of HLA-A11.1 mouse single HLA epitope vaccine is summarized in Table 20. The data were analyzed using IBM SPSS Statistics 25.0 statistical software, and the mean values of the detection data of different peptide libraries were compared between groups by One-Way ANOVA test; Graphpad Prism 8 software was used to perform overall comparisons between groups by Two-Way ANOVA test, and p < 0.05 was considered to be significantly different. The statistical analysis results are detailed in Table 21. Data display is shown in Fig.14 .
[0359] Table 20. Summary of the frequency of antigen-specific T cells in HLA-A11.1 mouse single HLA epitope vaccine (Mean±SD) Unit: SFU / 2*10^5 cells
[0360] Peptide library G1 G2 G3 G4 A11-P1 5±2 7±5 5±4 4±2 A11-P2 4±2 6±4 4±2 3±2 A11-P3 4±2 10±7 5±4 4±3 A11-P4 6±3 7±3 3±1 2±1 A11-LP1 7±3 10±8 31±16 13±12 A11-LP2 3±1 56±30 65±19 55±16 A11-LP3 4±4 17±5 19±13 16±8 A11-LP4 4±1 7±4 2±1 3±2
[0361] Table 21. Summary table of p-values of the frequency of antigen-specific T cells in HLA-A11.1 mouse single HLA epitope vaccine
[0362] Peptide library <![CDATA[G3 p a ]]> <![CDATA[G4 p a ]]> <![CDATA[G4 p b ]]> A11-P1 0.339 0.182 0.681 A11-P2 0.261 0.083 0.492 A11-P3 0.130 0.064 0.686 A11-P4 0.003** 0.002** 0.741 A11-LP1 0.022* 0.763 0.038* A11-LP2 0.556 0.929 0.499 A11-LP3 0.827 0.854 0.688 A11-LP4 0.013* 0.016* 0.910 Overall comparison 0.801 0.401 0.141
[0363] Note: p in p value a Compared with G2 group, p b For comparison with the G3 group; * , p<0.05; ** , p<0.01; *** , p<0.001.
[0364] The experimental results showed that the antigenic epitopes in the No. 2 long peptide library contained the most dominant antigenic epitopes that stimulated HLA-A11.1 transgenic mice after vaccine immunization, and positive reactions were also detected in the No. 1 and No. 3 long peptide libraries. The frequencies of reactive T cells in the four groups of short peptide libraries and the No. 4 long peptide library were relatively low. After stimulation with the LP1 peptide library, the frequency of antigen-specific T cells in the spleen cells of mice in the G3 group was significantly higher than that in the G2 and G4 groups (p<0.05). After stimulation with the P4 and LP4 peptide libraries, the frequency of antigen-specific T cells in the spleen cells of mice in the G2 group was significantly higher than that in the G3 and G4 groups. Taking different peptide libraries as analysis factors, the three groups were compared overall. The mean value of the G3 (ECVAC-A11-1.3) group was the highest, but there was no statistical difference between the groups.
[0365] 3. In vivo screening of optimized ECVAC-A2 / 11 sequences
[0366] The statistical analysis results of the HLA-A2.1 vaccine antigen-specific T cell frequency are shown in Table 22, and the data are presented in Fig.15 The data were analyzed using IBM SPSS Statistics 25.0 statistical software, and the mean values of the detection data of different peptide libraries were compared among the groups by One-Way ANOVA test; Graphpad Prism 8 software was used to perform overall comparisons among the groups by Two-Way ANOVA test, and p < 0.05 was considered to be significantly different.
[0367] The test results showed that the antigenic epitopes in peptide library No. 1 (including short peptide P1 and / or long peptide LP1) contained the most dominant antigenic epitopes that stimulated HLA-A2.1 transgenic mice to produce after vaccine immunization. Positive reactions were also detected in peptide libraries No. 2 and No. 3 (including short peptides and / or long peptides), among which A2 / 11-P2 had the weakest positive reaction. After stimulation with peptide library No. 1 (including P1 and LP1), the frequency of antigen-specific T cells in splenocytes of mice in the ECVAC-A2 / 11-1.2 group was significantly higher than that in the ECVAC-A2 / 11-1.4 and ECVAC-A2 / 11-1.5 groups (p<0.05). After stimulation with the A2 / 11-P2 peptide library, the frequency of antigen-specific T cells in splenocytes of mice in the ECVAC-A2 / 11-1.5 group was significantly higher than that in the ECVAC-A2 / 11-1.4 group. Using different peptide libraries as analysis factors, an overall intergroup comparison was performed among the three groups. The ECVAC-A2 / 11-1.2 group was significantly better than the ECVAC-A2 / 11-1.4 and ECVAC-A2 / 11-1.5 groups, and there was no significant difference between the ECVAC-A2 / 11-1.4 and ECVAC-A2 / 11-1.5 groups.
[0368] Table 22. Summary table of p-values of HLA-A2.1 mouse vaccine antigen-specific T cell frequency statistical analysis
[0369] Peptide library 1.2 VS 1.4 1.2 VS 1.5 1.4 VS 1.5 A2 / 11-P1 0.007** 0.008** 0.923 A2 / 11-P2 0.521 0.253 0.008** A2 / 11-P3 0.500 0.374 0.309 A2 / 11-LP1 0.005** 0.006** 0.891 A2 / 11-LP2 0.471 0.513 0.686 A2 / 11-LP3 0.494 0.351 0.129 Overall comparison <0.001*** <0.001*** 0.987
[0370] Note: * , p<0.05; ** , p<0.01; *** , p<0.001.
[0371] The statistical analysis results of the HLA-A11.1 vaccine antigen-specific T cell frequency are shown in Table 23 and the data are presented in Fig.16 The data were analyzed using IBM SPSS Statistics 25.0 statistical software, and the mean values of the detection data of different peptide libraries were compared among the groups by One-Way ANOVA test; Graphpad Prism 8 software was used to perform overall comparisons among the groups by Two-Way ANOVA test, and p < 0.05 was considered to be significantly different.
[0372] The test results showed that positive reactions could be detected in peptide libraries No. 4, No. 5, and No. 6 (including short peptides and / or long peptides), among which A2 / 11-P5 had the weakest positive reaction. Due to the large individual differences within the group, the peptide library where the dominant epitope is located is not yet obvious. After stimulation with the A2 / 11-LP5 peptide library, the frequency of antigen-specific T cells in the spleen cells of mice in the ECVAC-A2 / 11-1.4 group was significantly higher than that in the ECVAC-A2 / 11-1.5 group (p<0.05). Taking different peptide libraries as analysis factors, an overall inter-group comparison was performed on the three groups. The ECVAC-A2 / 11-1.2 group had the highest mean value, but there was no statistical difference with the ECVAC-A2 / 11-1.4 and ECVAC-A2 / 11-1.5 groups.
[0373] Table 23. Summary table of p-values of HLA-A11.1 mouse vaccine antigen-specific T cell frequency statistical analysis
[0374] Peptide library 1.2 VS 1.4 1.2 VS 1.5 1.4 VS 1.5 A2 / 11-P4 0.642 0.606 0.875 A2 / 11-P5 0.923 0.961 0.884 A2 / 11-P6 0.671 0.681 0.972 A2 / 11-LP4 0.847 0.441 0.340 A2 / 11-LP5 0.050 0.917 0.042* A2 / 11-LP6 0.193 0.794 0.288 Overall comparison 0.868 0.231 0.490
[0375] Note: * , p<0.05; ** , p<0.01; *** , p<0.001.
[0376] According to the above animal test results, among the three groups of ECVAC-A2 / 11 vaccine optimization sequences, the ECVAC-A2 / 11-1.2 group test vaccine had the strongest immunogenicity in HLA-A2.1 mice, which was significantly better than the ECVAC-A2 / 11-1.4 and ECVAC-A2 / 11-1.5 groups, and was slightly stronger than the ECVAC-A2 / 11-1.4 and ECVAC-A2 / 11-1.5 groups in HLA-A11.1 mice, but there was no statistical difference.
[0377] In summary, the ECVAC-A2 / 11-1.2 version performed best in both in vivo and in vitro screening tests, so ECVAC-A2 / 11-1.2 was determined as the final candidate drug molecule, hereinafter referred to as ECVAC.
[0378] Example 10: In vitro pharmacodynamic study of ECVAC
[0379] Due to the mechanism of action of ECVAC, specific human HLA and immune system are required to work. Existing animal models have certain limitations in evaluating the efficacy of ECVAC. In order to simulate the biological activity of ECVAC in the human body, this study verified the expansion effect and killing activity of antigen-specific T cells of human PBMC under the action of ECVAC in vitro. A total of 3 subjects (purchased from Miaoshun Biotechnology) were selected for this study. Their HLA subtypes were HLA-A*02:01 or HLA-A*11:01. CD14+ monocytes were obtained by magnetic bead sorting of PBMC (EasySep TM Human CD14 Positive Selection KitII, Stemcell, 17858) and T cells (EasySep TM Human TCell Iso Kit, Stemcell, 17951), according to the conventional process (Ali, Muhammad et al. Nature protocols vol. 14, 6 (2019): 1926-1943.), CD14+ monocytes were induced into DC cells and co-incubated with ECVAC-mRNA-LNP, so that DC cells can express and present ECVAC antigens. Then, they were co-cultured with homologous T cells at a certain ratio (between 1:1 and 1:10) to achieve in vitro induction and expansion of antigen-specific T cells. KYSE-410 is a human esophageal squamous cell carcinoma cell line with HLA-A*24:02. In order to evaluate the HLA-dependent tumor killing effect, this study overexpressed HLA-A*02:01 and HLA-A*11:01 on the basis of the KYSE-410 cell line, referred to as KYSE-410-A2.1 and KYSE-410-A11.1. The amplified antigen-specific T cells were co-incubated with KYSE-410 of different HLA at different effector-target ratios to detect the killing effect of antigen-specific T cells amplified by ECVAC on tumor cells.
[0380] The experimental results are as follows Fig.17 As shown, strong T cell activation signals were detected in 1 of the 3 subjects with HLA-A*02:01 homozygous PBMC after ECVAC in vitro expansion. DCs without antigen treatment were used as the control group (DC+T), and DCs co-incubated with ECVAC were used as the experimental group (DC+ECVAC-mRNA-LNP). Compared with the control group, intracellular IFN-γ, TNF-α, CD107a and Granzyme-B in CD8+T cells were significantly upregulated after overnight stimulation with ECVAC antigen scanning peptide library at the end point of the experimental group ( Figure 3A), IFN-γ positive cell population increased from 0.59% to 4.92%, TNF-α positive cell population increased from 0.19% to 3.12%, CD107a positive cell population increased from 54.44% to 81.30%, Granzyme-B positive cell population increased from 28.46% to 61.04%.
[0381] The cell killing results showed ( Fig.17 B and C), antigen-specific T cells amplified by ECVAC have a significant killing effect on KYSE-410-A2.1, and the killing rate increases with the increase of the target ratio. At a high-efficiency target ratio of 100:1, the killing rate of tumor cells can reach 61.76%. The control group without ECVAC has no killing effect, and both groups of cells have no killing effect on KYSE-410, indicating that this killing effect is a killing reaction mediated by specific HLA-restricted and antigen-specific T cells.
[0382] In summary, ECVAC can effectively expand antigen-specific T cells in human PBMCs in vitro and exert a strong anti-tumor effect. In the absence of an ideal animal model, the biological activity of ECVAC in humans was explored at the in vitro level.
[0383] Example 11: Ex vivo pharmacodynamic study of ECVAC
[0384] HLA-A2.1 transgenic mice express the interspecies hybrid class I MHC gene HHD, which contains the α-1 and α-2 domains of the human HLA-A2.1 gene and the α-3 transmembrane structure and cytoplasmic domain alleles of the mouse H-2Db gene. This transgenic mouse can simulate the immune response of T cells to antigens presented by HLA-A2.1 and can be used to study the immune effect of HLA-restricted vaccines. HLA-A11.1 transgenic mice have the same characteristics as HLA-A2.1 transgenic mice except for the different HLA type. MC38 is a mouse colorectal cancer cell line that is often used to study the immune function of anti-tumor drugs. In this study, the endogenous MHC of MC38 cells was knocked out and the HLA-A*02:01 / H-2Db or HLA-A*11:01 / H-2Db chimeric genes were overexpressed to form MC38-A2.1-HHD and MC38-A11.1-HHD cell lines. Based on these two cell lines, the antigen fragments in ECVAC were overexpressed to form MC38-A2.1-HHD-EC and MC38-A11.1-HHD-EC cell lines for in vitro killing activity studies.
[0385] HLA-A2.1 and HLA-A11.1 transgenic mice (purchased from Biocytogen, catalog numbers 110110 and 112803) were injected intramuscularly with ECVAC LNP, 7 days apart, for a total of 3 injections. At the same time, the same immunization procedure was set up, and the control group was injected with PBS. The mice were killed on the 3rd day after the last immunization, and the spleen was prepared into a single cell suspension, and T cells were sorted by magnetic beads. After the above-mentioned modified MC38 cell line was transfected with luciferase mRNA, the target cells were indicated, and the sorted T cells were co-incubated with different target cells at different effector-target ratios for 24 hours, and the killing of target cells by effector cells after reaction immunization was detected by luciferase activity.
[0386] The experimental results are as follows Fig.18 As shown in the figure, after HLA-A2.1 transgenic mice were immunized with ECVAC, the T cells in the spleen could effectively kill MC38-A2.1-HHD-EC, and the killing efficiency could reach 79.65% when the effector-target ratio was 40:1, but there was no killing effect on MC38-A2.1-HHD. Similarly, after HLA-A11.1 transgenic mice were immunized with ECVAC, the T cells in the spleen could effectively kill MC38-A11.1-HHD-EC, and the killing efficiency could reach 73.28% when the effector-target ratio was 10:1, and the killing efficiency could reach 93.24% when the effector-target ratio was 40:1, but there was no killing effect on MC38-A11.1-HHD. Whether it was the PBS group of HLA-A2.1 or HLA-A11.1 mice, their T cells had no killing effect on the four target cells, indicating that this killing effect was an HLA-dependent killing reaction mediated by antigen-specific T cells.
[0387] In summary, both HLA-A2.1 and HLA-A11.1 transgenic mice immunized with ECVAC can produce specific T cells against ECVAC antigens and have in vitro antitumor activity.
[0388] Example 12: In vivo pharmacodynamic study of ECVAC
[0389] To evaluate the in vivo efficacy of ECVAC, this study used HLA-A2.1 and HLA-A11.1 transgenic mice (purchased from Biocytogen, catalog numbers 110110 and 112803) and subcutaneously injected MC38-A2.1-HHD-EC or MC38-A11.1-HHD-EC tumor cells as in vivo efficacy models to verify the in vivo anti-tumor effect of ECVAC.
[0390] On the 4th day after the mice were tumor-bearing, the mice were randomly divided into two groups. One group was used as the treatment group (Vaccine), and ECVAC LNP was injected intramuscularly at intervals of 7 days for a total of 3 injections. The other group was injected with PBS as the control group after the same immunization procedure. The tumor volume was measured every 3 days after grouping, and the tumor growth inhibition rate TGITV (%) was calculated at the end of the experiment. TGITV (%) = 1-(T / C) × 100%, where T / C = treatment group evaluation TV / control group average TV (Tumor Volume, tumor volume).
[0391] The results are as follows Fig.19 As shown, on the 20th day after tumor bearing, the average tumor volume of ECVAC vaccine group was much smaller than that of PBS control group, regardless of HLA-A2.1 or HLA-A11.1 transgenic mice. TGITV of ECVAC vaccine group in HLA-A2.1 mice was 79.56% (P=0.0012), and TGITV of ECVAC vaccine group in HLA-A11.1 mice was 83.61% (P=0.0018).
[0392] In summary, the in vivo tumor-suppressing effect of ECVAC was demonstrated in both HLA-A2.1 and HLA-A11.1 tumor-bearing mouse models, indicating that ECVAC can be used to treat tumors with HLA subtypes of HLA-A*02:01 or HLA-A*11:01.
[0393] Example 13: In vivo pharmacodynamic study of ECVAC combined with anti-PD-1 antibody
[0394] MC38-A2.1-HHD-EC cells were inoculated subcutaneously in the flank of HLA-A2.1 Tg mice (purchased from Biocytogen, catalog number 110110, 69 mice in total) (the day of inoculation was recorded as D0). Starting from D4, 34 animals were randomly immunized with ECVAC LNP, referred to as ECVAC, and the remaining 35 animals were immunized with empty LNP, referred to as LNP. Each animal was immunized with 2 μg each time. The second and third immunizations were performed on D11 and D18. When the average tumor volume reached 60 mm 3Around 14:00 p.m. (D11), animals immunized with ECVAC and LNP were randomly divided into 6 groups according to tumor volume for treatment (the day of grouping was recorded as PG-D0), namely LNP+Isotype Ab 1.6 mg / kg (G1), ECVAC+Isotype Ab 1.6 mg / kg (G2), LNP+anti-mPD-1 0.4 mg / kg (G3), LNP+anti-mPD-1 1.6 mg / kg (G4), ECVAC+anti-mPD-1 0.4 mg / kg (G5), and ECVAC+anti-mPD-1 1.6 mg / kg (G6), with 6 animals in each group. Animals in groups G1 to G6 were administered with Isotype Ab or anti-mPD-1 via the tail vein once every 4 days, for a total of 4 times. The tumor volume and body weight of mice were measured 3 times a week after grouping and administration. The tumor growth inhibition rate (TGITV) of the treatment group was calculated and statistically analyzed.
[0395] After group administration, mice in each group ate and drank normally, and there was no significant trend of weight loss. There were no abnormal symptoms and they were generally in good condition. By the end of the experiment (PG-D19), compared with LNP+Isotype Ab 1.6mg / kg (G1), the TGI of ECVAC+IsotypeAb 1.6mg / kg (G2), LNP+anti-mPD-1 0.4mg / kg (G3), LNP+anti-mPD-11.6mg / kg (G4), ECVAC+anti-mPD-1 0.4mg / kg (G5) and ECVAC+anti-mPD-1 1.6mg / kg (G6) groups was significantly lower than that of LNP+Isotype Ab 1.6mg / kg (G1). TV (%) were 55%, 55%, 60%, 68% and 75% respectively. Statistical analysis results showed that at PG-D19, except for LNP+anti-mPD-1 0.4mg / kg (G3), the tumor volumes of the other treatment groups were significantly lower than those of the control group (P<0.05). The tumor inhibition effect of the combination group was better than that of the single-drug group. These results suggest that the combination of ECVAC and anti-mPD-1 has a better tumor inhibition effect than ECVAC or anti-mPD-1 alone. Tumor growth curve is shown in Fig. 20 The tumor growth inhibition effects are summarized in Table 24.
[0396] Table 24. Antitumor effects of the test substances
[0397]
[0398] Note: a. Mean ± standard error; b. Compared with group G1; c. Comparison between group G5 and group G3, and between group G6 and group G4; d. Comparison between group G6, G5 and group G2.
[0399] In summary, in the MC38-A2.1-HHD-ECVAC tumor-bearing model, both the single-drug group and the combination group had significant tumor inhibition effects; the combination of ECVAC and anti-mPD-1 had a better tumor inhibition effect than ECVAC or anti-mPD-1 alone. In addition, tumor-bearing animals had good tolerance to all tested drugs.
[0400] Incorporated by Reference
[0401] Each patent and scientific article mentioned herein is incorporated by reference in its entirety for all purposes.
[0402] Equivalence
[0403] The present disclosure may be embodied in other specific ways without departing from its spirit or essential characteristics. Therefore, the above embodiments should be regarded as illustrative in all cases, rather than limiting the invention described herein. Therefore, the scope of the present disclosure is indicated by the appended claims rather than by the above description, and all changes within the equivalent meaning and scope of the claims are intended to be covered therein.
Claims
1. A polypeptide comprising one or more targeting antigen fragments, wherein the antigen fragments comprise one or more antigen epitope peptides, and the one or more antigen fragments are connected by a connecting peptide, wherein the antigen is selected from one or more of ACTL8, BRDT, FOXI3, GNGT1, SMC1B, PLAC1, MAGEA1, MAGEA3, MAGEA4, MAGEA6, MAGEA10 and MAGEA11; preferably, the antigen further comprises one or more of TP53.175R / H, TP53.220Y / C, PIK3CA.545E / K and KRAS.12G / D.
2. The polypeptide of claim 1, wherein the antigenic fragment comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 108-162.
3. The polypeptide of claim 1, wherein the polypeptide comprises: 1) 20 antigen fragments, each of which is an amino acid sequence selected from SEQ ID NOs: 108-127; 2) 20 antigen fragments, each of which is an amino acid sequence selected from SEQ ID NOs: 128-147; or 3) 15 antigen fragments, each of which is an amino acid sequence selected from SEQ ID NOs: 148-162.
4. The polypeptide according to claim 1, wherein the antigenic epitope peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-107 or SEQ ID NOs: 163-225.
5. The polypeptide according to claim 1, comprising: (1) an antigenic epitope peptide targeting ACTL8, wherein the antigenic epitope peptide comprises an amino acid sequence shown in SEQ ID NOs: 3 or 7; (2) an antigenic epitope peptide targeting SMC1B, wherein the antigenic epitope peptide comprises an amino acid sequence shown in SEQ ID NO: 28; (3) an antigenic epitope peptide targeting FOXI3, wherein the antigenic epitope peptide comprises an amino acid sequence shown in SEQ ID NO: 12; (4) an antigenic epitope peptide targeting GNGT1, wherein the antigenic epitope peptide comprises an amino acid sequence shown in SEQ ID NO: 13; (5) An antigenic epitope peptide targeting PLAC1, wherein the antigenic epitope peptide comprises: (i) the amino acid sequence shown in SEQ ID NO: 23 or SEQ ID NO: 163; (ii) the amino acid sequence shown in SEQ ID NO: 164; and (iii) the amino acid sequence shown in SEQ ID NO: 165; (6) an antigenic epitope peptide targeting BRDT, wherein the antigenic epitope peptide comprises an amino acid sequence shown in SEQ ID NO: 9; (7) an antigenic epitope peptide targeting MAGEA1, wherein the antigenic epitope peptide comprises an amino acid sequence shown in SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 63, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168 or SEQ ID NO: 169; (8) An antigenic epitope peptide targeting MAGEA4, the antigenic epitope peptide comprising: (i) the amino acid sequence shown in SEQ ID NO: 19, SEQ ID NO: 70, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172 or SEQ ID NO: 173; and (ii) the amino acid sequence shown in SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:174, SEQ ID NO:175 or SEQ ID NO:176; (9) An antigenic epitope peptide targeting MAGEA6, the antigenic epitope peptide comprising: (i) the amino acid sequence shown in SEQ ID NO: 177, SEQ ID NO: 178 or SEQ ID NO: 179; and (ii) the amino acid sequence shown in SEQ ID NO: 180; (10) An antigenic epitope peptide targeting MAGEA3, the antigenic epitope peptide comprising: (i) the amino acid sequence shown in SEQ ID NO: 181, SEQ ID NO: 182 or SEQ ID NO: 183; and (ii) the amino acid sequence shown in SEQ ID NO: 184; (11) An antigenic epitope peptide targeting MAGEA11, the antigenic epitope peptide comprising: (i) the amino acid sequence shown in SEQ ID NO: 185, SEQ ID NO: 186 or SEQ ID NO: 187; and (ii) the amino acid sequence shown in SEQ ID NO: 15, SEQ ID NO: 188 or SEQ ID NO: 189; (12) An antigenic epitope peptide targeting MAGEA10, the antigenic epitope peptide comprising: (i) the amino acid sequence shown in SEQ ID NO: 14, SEQ ID NO: 190, SEQ ID NO: 191 or SEQ ID NO: 192; and (ii) the amino acid sequence shown in SEQ ID NO: 193 or SEQ ID NO: 194; (13) an antigenic epitope peptide targeting TP53.175R / H, wherein the antigenic epitope peptide comprises the amino acid sequence shown in SEQ ID NO: 195; and (14) An antigenic epitope peptide targeting TP53.220Y / C, wherein the antigenic epitope peptide comprises the amino acid sequence shown in SEQ ID NO:
196.
6. The polypeptide according to claim 1, comprising: (1) An antigenic epitope peptide targeting SMC1B, the antigenic epitope peptide comprising: (i) the amino acid sequence shown in SEQ ID NOs:93, SEQ ID NOs:101 or SEQ ID NOs:106; and (ii) the amino acid sequence shown in SEQ ID NOs: 104; (2) An antigenic epitope peptide targeting BRDT, the antigenic epitope peptide comprising: (i) the amino acid sequence shown in SEQ ID NO: 42 or SEQ ID NO: 46; and (ii) the amino acid sequence shown in SEQ ID NO: 50; (3) an antigenic epitope peptide targeting GNGT1, wherein the antigenic epitope peptide comprises the amino acid sequences shown in SEQ ID NO: 54 and SEQ ID NO: 55; (4) an antigenic epitope peptide targeting FOXI3, wherein the antigenic epitope peptide comprises the amino acid sequence shown in SEQ ID NO: 53; (5) an antigenic epitope peptide targeting ACTL8, wherein the antigenic epitope peptide comprises the amino acid sequences shown in SEQ ID NO: 40 and SEQ ID NO: 31; (6) An antigenic epitope peptide targeting MAGEA6, the antigenic epitope peptide comprising: (i) the amino acid sequence shown in SEQ ID NO: 73 or SEQ ID NO: 78; and (ii) the amino acid sequence shown in SEQ ID NO: 74; (7) an antigenic epitope peptide targeting MAGEA11, wherein the antigenic epitope peptide comprises the amino acid sequences shown in SEQ ID NO: 59 and SEQ ID NO: 60; (8) an antigenic epitope peptide targeting MAGEA3, wherein the antigenic epitope peptide comprises the amino acid sequences shown in SEQ ID NO: 197 and SEQ ID NO: 65; (9) an antigenic epitope peptide targeting MAGEA4, wherein the antigenic epitope peptide comprises the amino acid sequences shown in SEQ ID NO: 71 and SEQ ID NO: 72; (10) an antigenic epitope peptide targeting MAGEA10, wherein the antigenic epitope peptide comprises the amino acid sequence shown in SEQ ID NO: 57; (11) An antigenic epitope peptide targeting MAGEA1, the antigenic epitope peptide comprising: (i) the amino acid sequence shown in SEQ ID NO:61, SEQ ID NO:62 or SEQ ID NO:198; and (ii) the amino acid sequence shown in SEQ ID NO: 199, SEQ ID NO: 200 or SEQ ID NO: 201; (12) an antigenic epitope peptide targeting PIK3CA.545E / K, wherein the antigenic epitope peptide comprises the amino acid sequence shown in SEQ ID NO: 202; and (13) An antigenic epitope peptide targeting KRAS.12G / D, wherein the antigenic epitope peptide comprises the amino acid sequence shown in SEQ ID NO:
203.
7. The polypeptide of claim 1, comprising: (1) An antigenic epitope peptide targeting ACTL8, the antigenic epitope peptide comprising: (i) the amino acid sequence shown in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:36 or SEQ ID NO:38; and (ii) the amino acid sequence shown in SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 34 or SEQ ID NO: 40; (2) An antigenic epitope peptide targeting GNGT1, wherein the antigenic epitope peptide comprises: (i) the amino acid sequence shown in SEQ ID NO: 13 or SEQ ID NO: 54; and (ii) the amino acid sequence shown in SEQ ID NO: 55; (3) An antigenic epitope peptide targeting MAGEA1, wherein the antigenic epitope peptide comprises: (i) the amino acid sequence set forth in SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218 or SEQ ID NO:219; and (ii) the amino acid sequence set forth in SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 63, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 220, SEQ ID NO: 221 or SEQ ID NO: 222; (4) An antigenic epitope peptide targeting MAGEA6, wherein the antigenic epitope peptide comprises: (i) the amino acid sequence shown in SEQ ID NO: 208 or SEQ ID NO: 77; (ii) the amino acid sequence shown in SEQ ID NO: 180 or SEQ ID NO: 223; and (iii) the amino acid sequence shown in SEQ ID NO: 209; (5) An antigenic epitope peptide targeting MAGEA3, wherein the antigenic epitope peptide comprises: (i) the amino acid sequence shown in SEQ ID NO: 67; (ii) the amino acid sequence shown in SEQ ID NO: 210, SEQ ID NO: 211 or SEQ ID NO: 212; (iii) the amino acid sequence shown in SEQ ID NO: 213; and (iv) the amino acid sequence shown in SEQ ID NO: 184 or SEQ ID NO: 65; (6) An antigenic epitope peptide targeting SMC1B, the antigenic epitope peptide comprising: (i) the amino acid sequence shown in SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:185, SEQ ID NO:94, SEQ ID NO:105, SEQ ID NO:95 or SEQ ID NO:89; (ii) the amino acid sequence shown in SEQ ID NO: 81 or SEQ ID NO: 99; and (iii) the amino acid sequence shown in SEQ ID NO: 27 or SEQ ID NO: 80; (7) An antigenic epitope peptide targeting MAGEA4, the antigenic epitope peptide comprising: (i) the amino acid sequence shown in SEQ ID NO:70, SEQ ID NO:19, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172 or SEQ ID NO:173; and (ii) the amino acid sequence shown in SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176 or SEQ ID NO:214; (8) an antigenic epitope peptide targeting MAGEA11, wherein the antigenic epitope peptide comprises an amino acid sequence shown in SEQ ID NO: 15, SEQ ID NO: 188, SEQ ID NO: 189, SEQ ID NO: 58 or SEQ ID NO: 60; (9) An antigenic epitope peptide targeting BRDT, wherein the antigenic epitope peptide comprises the amino acid sequence shown in SEQ ID NO: 11, SEQ ID NO: 43 or SEQ ID NO:
45.
8. The polypeptide according to any one of claims 1 to 7, comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 226-228.
9. The polypeptide according to claim 1, wherein the C-terminus of the polypeptide further comprises a Th cell epitope PADRE and a major histocompatibility complex (MHC) class I transmembrane and transport domain (MITD).
10. The polypeptide of claim 1, wherein the N-terminus of the polypeptide comprises a signal peptide. The polypeptide according to claim 1 , wherein the connecting peptide is a sequence as shown in SEQ ID NO: 235-236.
12. The polypeptide according to any one of claims 1 to 11, wherein the polypeptide is selected from the amino acid sequences shown in SEQ ID NOs: 229-231.
13. A linear epitope peptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 1-107 and SEQ ID NOs: 163-225; preferably, the epitope peptide targets one or more antigens selected from the group consisting of ACTL8, BRDT, FOXI3, GNGT1, SMC1B, PLAC1, MAGEA1, MAGEA3, MAGEA4, MAGEA6, MAGEA10 and / or MAGEA11.
14. The linear epitope peptide according to claim 13, wherein the linear epitope peptide is selected from one or more of the following: (1) a linear epitope peptide targeting ACTL8, comprising an amino acid sequence selected from SEQ ID NOs: 1-7 and SEQ ID NOs: 29-41; (2) a linear epitope peptide targeting BRDT, comprising an amino acid sequence selected from SEQ ID NOs: 8-11 and SEQ ID NOs: 42-52; (3) a linear epitope peptide targeting FOXI3, comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 12 and SEQ ID NO: 53; (4) a linear epitope peptide targeting GNGT1, comprising an amino acid sequence selected from SEQ ID NOs: 13 and SEQ ID NOs: 54-56; (5) a linear epitope peptide targeting SMC1B, comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 24-28, SEQ ID NOs: 79-107, and SEQ ID NO: 185; (6) a linear epitope peptide targeting PLAC1, comprising an amino acid sequence selected from SEQ ID NO: 23 and SEQ ID NOs: 163-165; (7) a linear epitope peptide targeting MAGEA1, comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 16-17, SEQ ID NOs: 61-63, SEQ ID NOs: 166-169, SEQ ID NOs: 198-201, and SEQ ID NOs: 204-207; (8) a linear epitope peptide targeting MAGEA3, comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NOs: 64-68, SEQ ID NOs: 181-184, SEQ ID NO: 197, and SEQ ID NOs: 210-213; (9) a linear epitope peptide targeting MAGEA4, comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 19-21, SEQ ID NOs: 69-72, SEQ ID NOs: 170-176, SEQ ID NO: 214, and SEQ ID NOs: 224-225; (10) a linear epitope peptide targeting MAGEA6, comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 22, SEQ ID NOs: 73-78, SEQ ID NOs: 177-180, SEQ ID NOs: 208-209 and SEQ ID NO: 223; (11) a linear epitope peptide targeting MAGEA10, comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 57, and SEQ ID NOs: 190-194; and (12) A linear epitope peptide targeting MAGEA11, comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NOs: 58-60, and SEQ ID NOs: 185-189.
15. A nucleic acid comprising a nucleotide sequence encoding the polypeptide according to any one of claims 1 to 12 or the linear epitope peptide according to any one of claims 13 to 14.
16. An RNA nucleic acid molecule comprising an open reading frame encoding a polypeptide as described in any one of claims 1 to 12; preferably, the RNA nucleic acid molecule comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 237-256.
17. A tumor-associated antigen vaccine, comprising the RNA nucleic acid molecule as shown in claim 16; preferably, the RNA nucleic acid molecule is mRNA; preferably, the vaccine is prepared using lipid nanoparticles (LNP).
18. A pharmaceutical composition comprising the polypeptide according to any one of claims 1 to 12, the linear epitope peptide according to any one of claims 13 to 14, the nucleic acid according to claim 15, the RNA nucleic acid molecule according to claim 16, or the tumor-associated antigen vaccine according to claim 17.
19. Use of the polypeptide according to any one of claims 1 to 12, the linear epitope peptide according to any one of claims 13 to 14, the nucleic acid according to claim 15, the RNA nucleic acid molecule according to claim 16, the tumor-associated antigen vaccine according to claim 17 or the pharmaceutical composition according to claim 18 in the preparation of a medicament for treating and preventing a disease in a subject; preferably, the disease is selected from esophageal squamous cell carcinoma, lung squamous cell carcinoma, hepatocellular carcinoma, gastric cancer, lung adenocarcinoma, colon cancer and rectal cancer; preferably, the subject is preferably a human.
Citation Information
Cited By
Universal mRNA (messenger ribonucleic acid) tumor vaccine and preparation method and application thereof
CN120590547A
T cell receptors (TCRS) targeting actin-like protein 8 (ACTL8) for use in therapy
WO2026190372A1
